

Supporting Information

A General Enantioselective and Stereochemically Divergent Four-Stage Approach to Fused Tetracyclic Terpenoid Systems

Joshua M. Nicholson,[†] Adam B. Millham,[†] Andrea R. Bucknam, Lauren E. Markham,
Xenia E. Sailors and Glenn C. Micalizio*

Department of Chemistry, Burke Laboratory, Dartmouth College, Hanover, NH 03755

For correspondence, please email glenn.c.micalizio@dartmouth.edu

Table of Contents:	Page
1. Materials and Methods	S2
2. Experimental Procedures	
A. Synthesis of TMS Alkynes	S4
B. Synthesis of Enynes	S5
C. Synthesis of Hydrindanes	S10
D. Initial studies on C9,C13-<i>Anti/Syn</i> Selective Reactions and Oxidative Shift	S19
E. Studies on the Effects of Substitution in the Friedel–Crafts Cyclization	S30
F. Synthesis of C9,C13-<i>Anti</i>-Substituted Tetracycles	S44
G. Synthesis of Tetracycle from Hajos–Parrish Ketone Derivative	S59
H. Synthesis of C9,C13-<i>Syn</i>-Substituted Tetracycles and Oxidative Shift	S63
3. NMR Spectra	S68
4. References	S134

1. Materials and Methods

A. Stereochemical Relationships

All stereochemical relationships depicted for products generated are the result of interpretation of both 1D and 2D NMR spectra. The relative stereochemistry between the C9 and 13 substituents was established via 1D nOe experiments, unless otherwise indicated.

B. Experimental Setups

All reactions were conducted in flame-dried glassware under an atmosphere of nitrogen and in anhydrous solvents unless otherwise indicated. Later examples utilized silylated glassware, azeotropically dried starting materials, and vacuum-dried BINOL. All reagents and starting materials were purchased from commercial sources and used as received, unless otherwise indicated. Anhydrous dichloromethane (CH_2Cl_2), diethyl ether (Et_2O), tetrahydrofuran (THF), and toluene (PhMe) were obtained by passing commercially available HPLC grade solvents through a column of activated alumina using a Glass Contour Solvent Purification System by Pure Process Technology LLC. Titanium isopropoxide ($\text{Ti}(\text{O}i\text{-Pr})_4$) was distilled prior to use and stored in a foil-wrapped round bottom flask under an atmosphere of nitrogen. Said flask was stored in a desiccator when not in use. *n*-BuLi was purchased from Sigma-Aldrich as a 2.5 M solution in hexanes and was titrated against *N*-benzylbenzamide according to a literature procedure¹ to accurately determine the titer before use. Percent yields correspond to chromatographically and spectroscopically (¹H NMR) homogeneous materials, unless otherwise stated. Flash chromatography was performed on a Biotage[®] Automated Liquid Chromatography System Isolera One[®] using Biotage[®] SNAP KP-Sil 10-25 g or Biotage[®] SNAP Ultra 25 μm HP-Sphere 10-50 g silica gel cartridges or performed using a forced flow of the indicated solvent system on Sorbent Technologies TM silica gel 60Å (40–63 μm particle size). Thin phase chromatography (TLC) analyses were performed on EMD TLC silica gel 60 F₂₃₄ glass plates and the compounds were visualized by exposure to UV light (254 nm) followed by staining with *p*-anisaldehyde, cerium ammonium molybdate, or KMnO_4 .


C. Spectral Analysis Information

¹H NMR spectra were recorded on a Bruker Avance III 500 MHz (TBI probe) or a 600 MHz (BBFO probe) spectrometer using chloroform-*d* (CDCl_3) as solvent for all samples. All signals are reported in parts per million (ppm) and calibrated to the residual protium signal of chloroform (CHCl_3 , 7.26 ppm). Signals are reported as δ chemical shifts in ppm (multiplicity, coupling constants in Hz, integration). ¹³C{¹H} NMR spectra were recorded on a Bruker Avance III 600 MHz (BBFO probe) spectrometer measured at 150 MHz or a Bruker Avance III 500 MHz (TBI probe) spectrometer measured at 125 MHz. All signals are reported in ppm and are calibrated to the central line of the residual solvent signal of CHCl_3 (77.2 ppm). Signals are reported as δ chemical shift(s) in ppm. Two-dimensional NMR spectra, including COSY, HSQC, HMBC, and NOESY were recorded on a Bruker Avance III 600 MHz spectrometer (BBFO probe), or a Bruker Avance III 500 MHz spectrometer (TBI probe). Infrared spectra were recorded on a JASCO FT/IR-4100 Fourier Transform Infrared Spectrometer. IR absorption is reported as strong (s), medium (m), weak (w), and/or broad (br). ESI-TOF high-resolution mass spectroscopy (HRMS) analyses were performed at the mass spectrometry laboratory of the University of Illinois at Urbana-Champaign. Optical rotations ($[\alpha]$) were obtained on a JASCO P-2000 polarimeter equipped with tungsten-halogen lamp (WI) and interface filter set to 589 nm, using a sample cell with a pathlength

of 100 mm. Specific rotations are reported as: $[\alpha]_{589}^{T(^{\circ}\text{C})}$: (c, solvent) and are based on the equation $[\alpha]_{589}^{T(^{\circ}\text{C})} = (100 \cdot [\alpha]) / (l \cdot c)$, where the concentration (c) is reported as g/2 mL and the pathlength (l) is in decimeters.

2. Experimental Procedures


A. Synthesis of TMS Alkynes:



Synthesis of TMS-Alkyne S2: Alkyne **S1** was generated by the reported procedure described by Sarpong *et al.*² To a stirring solution of 3-butynol (5 mL, 66 mmol, 1.2 equiv.) in THF (55 mL) at 0 °C was sequentially added NaH (60% in oil, 2.6 g, 66 mmol, 1.2 equiv.), TBAI (2.03 g, 5.5 mmol, 0.1 equiv), and benzyl bromide (6.5 mL, 55 mmol, 1 equiv). The reaction mixture was stirred for 30 min at 0 °C, before being warmed to rt and stirred overnight (about 16 h). The reaction was then quenched by the addition of saturated aqueous NH₄Cl and extracted with Et₂O (3 x 100 mL). The combined organic phases were washed with DI water (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Column chromatography (0–5% EtOAc in hexanes) afforded benzyl ether (**S1**) as a light-yellow oil which was used in a subsequent silylation reaction.

To a stirring solution of alkyne **S1**, in THF at -78 °C was added *n*-BuLi (26.4 mL, 66 mmol, 1.2 equiv, 2.5 M in hexanes) dropwise. The reaction mixture was stirred at -78 °C for 15 mins before the addition of TMSCl (8.37 mL, 66 mmol, 1.2 equiv) dropwise. The reaction mixture was then warmed to rt and stirred for 1 h after which time the reaction was quenched with saturated aqueous NH₄Cl (100 mL) and extracted with Et₂O (3 x 100 mL). The combined organic phases were dried over Na₂SO₄, filtered and concentrated *in vacuo* to afford the desired silylated alkyne **S2** (12.0 g, 51.6 mmol, 92% yield) as a clear oil.


Spectral Data for Compound S2: The spectral data for **S2** matched previously reported data by Shaw *et al.*³



Synthesis of TMS-Alkyne S4: Alkyne **S4** was generated by the reported procedure described by Tonks *et al.*⁴ To a stirring solution of alkyne **S3** (4.5 mL, 39.1 mmol, 1 equiv), in THF at -78 °C was added *n*-BuLi (16.8 mL, 42 mmol, 1.1 equiv, 2.5 M in hexanes) dropwise. The reaction mixture was stirred at -78 °C for 15 mins before the addition of TMSCl (5.35 mL, 42 mmol, 1.1 equiv) dropwise. The resulting solution was warmed to rt and stirred for 1 h after which time the reaction was quenched with saturated aqueous NH₄Cl (100 mL) and extracted with Et₂O (3 x 100 mL). The combined organic phases were dried over Na₂SO₄, filtered and concentrated *in vacuo* to afford the desired silylated alkyne **S4** (5.8 g, 37.58 mmol, 96% yield) as a clear oil.


Spectral Data for Compound S4: The spectral data for **S4** matched previously reported data by Tonks *et al.*⁴

B. Synthesis of Enynes:



Synthesis of Diol S6: To a stirring solution of zinc dust (4.71 g, 72.1 mmol, 3 equiv) in anhydrous THF (47 mL) at rt was added propargyl bromide (8.0 mL, 72.1 mmol, 3 equiv). The resulting solution was stirred for 2 h at rt. Then, 2-hydroxy-5-methoxybenzaldehyde **S5** (3 mL, 24.0 mmol, 1 equiv) was added dropwise. The reaction mixture was stirred for 17 h at rt, and progress was monitored by TLC. The reaction was quenched by the slow addition of saturated aqueous NH₄Cl. The biphasic solution was transferred to a separatory funnel and the phases were separated. The aqueous phase was extracted with EtOAc (3 x 50 mL), and the combined organic phase was washed with brine (2 x 50 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage[®] Snap Ultra 25 g cartridge and a gradient from 10–25% EtOAc in hexanes to afford **S6** (3.35 g, 17.4 mmol, 72%) as an orange oil.


Data for Compound S6: The spectral data for **S6** matched previously reported data by Xiang *et al.*⁵ For NMR Spectra of **S6** see page S69. **TLC:** R_f = 0.19 (30% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 6.80 (d, *J* = 8.8 Hz, 1H), 6.75 (dd, *J* = 8.8, 2.9 Hz, 1H), 6.61 (d, *J* = 2.8 Hz, 1H), 4.96 (dd, *J* = 8.9, 4.4 Hz, 1H), 3.75 (s, 3H), 2.80 (ddd, *J* = 16.9, 9.0, 2.5 Hz, 1H), 2.68 (ddd, *J* = 17.0, 4.5, 2.7 Hz, 1H), 2.15 (app. t, *J* = 2.4 Hz, 1H); **¹³C{¹H} NMR** (151 MHz, CDCl₃): δ 153.2, 149.1, 126.2, 118.1, 114.6, 112.9, 80.3, 73.5, 71.0, 55.9, 28.0.



Synthesis of Phenol S7: To a solution of the diol **S6** (0.20 g, 1.04 mmol, 1 equiv) in CH₂Cl₂ (2.1 mL) at rt was added triethylsilane (0.3 mL, 2.08 mmol, 2 equiv). Then, trifluoroacetic acid (0.3 mL, 4.16 mmol, 4 equiv) was added dropwise and the reaction was stirred at rt for 1 h and the progress of the reaction was monitored by TLC (20% EtOAc in hexanes). Upon completion, the reaction was quenched with saturated aqueous NaHCO₃, and the aqueous phase was extracted with CH₂Cl₂ (3 x 5 mL). The combined organic phases were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude product was purified by flash column chromatography on a Biotage[®] Sfär Silica HC D 10 g cartridge and a gradient from 0–20% EtOAc in hexanes to afford the phenol **S7** (0.128 g, 0.726 mmol, 69%) as a white solid.


Data for Compound S7: The spectral data for **S7** matched previously reported data by Xiang *et al.*⁵ For NMR Spectra of **S7** see page S70. **TLC:** R_f = 0.44 (30% EtOAc in hexanes); **¹H NMR** (600 MHz, Chloroform-*d*) δ 6.79 – 6.69 (m, 2H), 6.66 (dd, *J* = 8.7, 3.0 Hz, 1H), 4.76 – 4.65 (br, 1H), 3.76 (s, 3H), 2.84 (t, *J* = 7.3 Hz, 2H), 2.51 (td, *J* = 7.3, 2.6 Hz, 2H), 2.01 (app. t, *J* = 2.7 Hz,

¹H). ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 153.9, 147.6, 128.2, 116.6, 116.3, 112.67, 84.5, 69.3, 55.9, 30.0, 19.3.




Synthesis of Aryl Triflate S8: To anhydrous CH₂Cl₂ (61 mL) was added the phenol S7 (1.31 g, 7.45 mmol, 1 equiv), and the solution was cooled to -78°C . Triethylamine (1.24 mL, 8.94 mmol, 1.2 equiv) was added dropwise, and the reaction mixture became bright yellow. Then, a solution of triflic anhydride (1.25 mL, 7.45 mmol, 1 equiv) in CH₂Cl₂ (14 mL) was added dropwise, and the solution became clear. The reaction mixture was stirred at -78°C , and progress of the reaction was monitored by TLC (30% EtOAc in hexanes). The reaction was complete after 10 min and was quenched with saturated aqueous NaHCO₃. The organic phase was removed, and the aqueous phase was extracted with CH₂Cl₂ (3 x 50 mL). The combined organic phases were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude product was purified by flash column chromatography on a Biotage[®] KP-Sil 50 g cartridge and a gradient from 0–20% EtOAc in hexanes to afford the aryl triflate S1 (1.91g, 6.20 mmol, 83%) as an off-white oil.

Data for Compound S8: The spectral data for S8 matched previously reported data by Millham *et al.*⁶ For NMR Spectra of S8 see page S71. **TLC:** R_f = 0.56 (30% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.18 (d, *J* = 9.0 Hz, 1H), 6.91 (d, *J* = 3.0 Hz, 1H), 6.80 (dd, *J* = 9.0, 3.1 Hz, 1H), 3.82 (s, 3H), 2.91 (t, *J* = 7.3 Hz, 2H), 2.53 (td, *J* = 7.4, 2.6 Hz, 2H), 2.00 (app. t, *J* = 2.7 Hz, 1H); **¹³C{¹H} NMR** (151 MHz, CDCl₃): δ 159.0, 141.4, 134.4, 122.5, 121.9, 119.8, 117.7, 116.5, 115.3, 113.2, 82.8, 69.8, 55.8, 29.3, 19.0.



Synthesis of Enyne S10: To a round bottom flask was added the aryl triflate S8 (0.42 g, 1.39 mmol, 2.5 equiv) in THF (4.6 mL). The solution was cooled to -78°C , then *n*-BuLi (0.45 mL, 1.11 mmol, 2 equiv, 2.5 M in hexanes) was added dropwise. The resulting solution was stirred for 30 min at -78°C , then BF₃·OEt₂ (0.14 mL, 1.17 mmol, 2.1 equiv) was added dropwise, and the mixture was stirred an additional 30 min at -78°C . The epoxide S9⁷ (52 μL, 0.56 mmol, 1 equiv) was added dropwise, and the reaction mixture was stirred for 2 h at -78°C , and progress was monitored by TLC (30% EtOAc in hexanes). The reaction was quenched at -78°C with saturated aqueous NaHCO₃. The phases were separated and the aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic phases were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude product was purified by flash column chromatography on a Biotage[®] KP-Sil 25 g cartridge and a gradient from 0–20% EtOAc in hexanes to afford the enyne S10 (0.222 g, 0.546 mmol, 98%) as an off-white oil.

Data for Compound S10: The spectral data for **S10** matched previously reported data by Millham *et al.*⁶ For NMR Spectra of **S10** see page S72. **TLC:** $R_f = 0.42$ (30% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.17 (d, $J = 9.0$ Hz, 1H), 6.90 (d, $J = 3.1$ Hz, 1H), 6.78 (dd, $J = 9.0, 3.1$ Hz, 1H), 4.86 (s, 1H), 4.77 (s, 1H), 3.84 – 3.78 (m, 4H), 2.88 (app. t, $J = 7.3$ Hz, 2H), 2.54 – 2.51 (m, 2H), 2.39 – 2.28 (m, 2H), 2.23 (dd, $J = 13.8, 4.6$ Hz, 1H), 2.15 (dd, $J = 13.8, 8.5$ Hz, 1H), 1.92 (d, $J = 3.8$ Hz, 1H), 1.74 (s, 3H); **¹³C{¹H} NMR** (151 MHz, CDCl₃): δ 159.0, 142.5, 141.5, 134.8, 122.4, 121.9, 119.8, 117.7, 116.6, 115.6, 113.6, 113.0, 81.3, 77.8, 67.8, 55.8, 44.9, 29.7, 27.3, 22.6, 19.3.




Synthesis of Epoxide S12: To a solution of Grignard reagent **S11**⁸ (275 mL, 71.5 mmol, 0.26 M in THF, 1.15 equiv) at -78 °C was added CuI (2.72 g, 14.3 mmol, 0.23 equiv) with vigorous stirring. Then, (R)-epichlorohydrin (5.61 mL, 62.2 mmol, 1.0 equiv) was added. The reaction mixture was stirred at -78 °C for 10 mins, and the cooling bath was removed. Upon reaching rt, the reaction was quenched with saturated aqueous NH₄Cl, and diluted with Et₂O and water. The phases were separated, and the aqueous phase was extracted with Et₂O (2 x 30 mL). The combined organic extracts were washed with H₂O (50 mL) and half saturated brine (50 mL), dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude chlorohydrin was taken on to the next step without further purification.

The crude intermediate chlorohydrin was dissolved in CH₂Cl₂ (65 mL) and crushed NaOH (5.80 g, 145 mmol, 2.3 equiv) was added. The reaction mixture was stirred vigorously at rt for 24 h, and then filtered through a short pad of sand and filter paper in a Büchner funnel, using additional CH₂Cl₂ to wash forward. The filtrate was concentrated *in vacuo* to afford the crude epoxide **S12**, which was split into portions and used in the next step without further purification.

Synthesis of Enyne S14: Alkyne **S13**⁹ (6.78g, 42.3 mmol, 3.0 equiv) was dissolved in THF (45 mL) and cooled to -78 °C. *n*-BuLi (11.0 mL, 28.2 mmol, 2.5 M in hexanes, 2.0 equiv) was added dropwise, and the resulting solution was stirred at -78 °C for 30 mins. Then, BF₃·OEt₂ (4.35 mL, 35.3 mmol, 2.5 equiv) was added dropwise, and the reaction mixture was stirred at -78 °C for another 30 mins. Then, a solution of the epoxide **S12** (2.45 g, 14.1 mmol, 1 equiv) in THF (14 mL) was added dropwise. The resulting reaction mixture was stirred for another 1 h at -78 °C and was then quenched with saturated aqueous NaHCO₃ (20 mL). The phases were separated and the aqueous phase was extracted with EtOAc (4 x 25 mL). The combined organic extracts were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography (5–40% EtOAc in hexanes) to afford enyne **S14** (4.06 g, 13.5 mmol, 96%).

Data for Compound S14: For NMR Spectra of **S14** see page S73. **TLC:** R_f 0.38 (40% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.30 (dd, $J = 7.5$ Hz, 2H), 7.24 – 7.18 (m, 4H), 6.82–6.76 (m, 3H), 4.95 (s, 1H), 4.90 (s, 1H), 3.88 – 3.83 (m, 1H), 3.80 (s, 3H), 3.40 (d, $J = 15.1$ Hz, 1H), 3.37 (d, $J = 15.1$ Hz, 1H), 2.78 (app. t, $J = 7.5$ Hz, 2H), 2.49 – 2.46 (m, 2H), 2.40 – 2.30 (m,


2H), 2.25 (dd, $J = 14.2, 4.9$ Hz, 1H), 2.14 (dd, $J = 14.2, 8.2$ Hz, 1H), 1.99 (d, $J = 3.82$ Hz, 1H); $^{13}\text{C}\{\text{1H}\}$ NMR (150 MHz, CDCl_3): δ 159.7, 145.7, 142.5, 139.3, 129.4, 129.2, 128.5, 126.4, 120.9, 114.6, 114.4, 111.6, 82.5, 77.0, 68.1, 55.2, 43.1, 42.4, 35.4, 27.3, 20.9; IR (thin film, cm^{-1}): 3446 (br, m), 3061 (w), 3026 (m), 3000 (w), 2933 (s), 2911 (s), 2835 (m), 1644 (m), 1602 (s), 1584 (s), 1492 (s), 1453 (s), 1436 (s), 1261 (s), 1153 (s), 1075 (m), 1052 (s), 898 (m), 778 (m), 742 (s), 698 (s); HRMS (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{27}\text{O}_2$ 335.2011; found, 335.2009, $[\alpha]_{589}^{21.2} = -11.5$ (c 1.03, CHCl_3).



Synthesis of Epoxide S16: To a stirring solution of vinyl bromide **S15**¹⁰ (5.00 g, 19.6 mmol, 1.0 equiv) in THF (70 mL) at -78 °C in a 200 mL round-bottom flask was added n -BuLi (11.8 mL, 29.4 mmol, 1.5 equiv, 2.5 M in hexanes). The solution was stirred for 30 min before the dropwise addition of $\text{BF}_3 \cdot \text{OEt}_2$ (2.67 mL, 21.6 mmol, 1.1 equiv) then (R)-epichlorohydrin (1.69 mL, 21.6 mmol, 1.10 equiv) as a solution in THF (8 mL). The resulting mixture was stirred at -78 °C for 5 min before being warmed to rt, then was stirred for 1 h before addition of saturated aqueous NH_4Cl (20 mL). The phases were separated, the aqueous phase was extracted with EtOAc (3 x 30 mL), and the combined organic phase was dried over Na_2SO_4 , filtered, and concentrated *in vacuo*. The resulting crude material was used in the next step without purification.

To the crude material was added CH_2Cl_2 (40 mL) and NaOH (1.57 g, 39.2 mmol, 2.0 equiv) and the solution was stirred at rt overnight. The reaction was quenched with H_2O (20 mL) and the phases were separated. The aqueous phase was extracted with CH_2Cl_2 (3 x 20 mL) and the combined organic phase was dried over Na_2SO_4 , filtered through celite, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage® Sfär 50 g cartridge and a gradient from 5–35% EtOAc in hexanes to afford epoxide **S16** (2.34 g, 10.1 mmol, 52%) as a pale, yellow oil.


Data for Compound S16: For NMR Spectra of **S16** see page S74. TLC: $R_f = 0.38$ (20% EtOAc in hexanes); ^1H NMR (600 MHz, CDCl_3): δ 7.36 – 7.32 (m, 4H), 7.30 – 7.27 (m, 1H), 4.90 (s, 1H), 4.86 (s, 1H), 4.50 (d, $J = 2.4$ Hz, 2H), 3.49 (td, $J = 6.4, 2.1$ Hz, 2H), 3.05 – 3.00 (m, 1H), 2.80 – 2.78 (m, 1H), 2.51 – 2.47 (m, 1H), 2.31 – 2.25 (m, 1H), 2.23 – 2.14 (m, 3H), 1.81 – 1.75 (m, 2H); $^{13}\text{C}\{\text{1H}\}$ NMR (150 MHz, CDCl_3): δ 145.4, 138.7, 128.5, 127.8, 127.7, 111.5, 73.1, 69.9, 51.3, 47.1, 39.4, 33.2, 27.9; IR (neat, cm^{-1}): 3031 (m), 2987 (m), 2923 (s), 2855 (s), HRMS (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{21}\text{O}_2$ 233.1542; found, 233.1534; $[\alpha]_{589}^{22.1} = +7.7$ (c 0.0023, CHCl_3).



Synthesis of Enyne S17: To a stirring solution of **S13**⁹ (4.05 g, 25.3 mmol, 2.5 equiv) in THF (70 mL) in a 200 mL round-bottom flask was added *n*-BuLi (6.10 mL, 15.2 mmol, 1.5 equiv, 2.5 M in hexanes). The solution was stirred for 30 min before BF₃•OEt₂ (2.54 mL, 20.2 mmol, 2.0 equiv), was added. After an additional 30 min **S16** (2.34 g, 10.1 mmol, 1.0 equiv) was added as a solution in THF (10 mL). The resulting mixture was stirred at -78 °C for 45 min before being quenched with saturated aqueous NaHCO₃ (20 mL) and then warmed to rt. The reaction mixture was diluted with EtOAc (30 mL) and the phases were separated. The aqueous phase was extracted with EtOAc (3 x 30 mL), and the combined organic phases were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a gradient from 5–35% EtOAc in hexanes to afford enyne **S17** (2.88 g, 7.34 mmol, 73%) as an orange oil.

Data for Compound S17: For NMR Spectra of **S17** see page S75. **TLC:** R_f = 0.15 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.37 – 7.31 (m, 4H), 7.30 – 7.27 (m, 1H), 7.20 (app. t, *J* = 7.8 Hz, 1H), 6.80 (d, *J* = 7.5 Hz, 1H), 6.77 – 6.73 (m, 2H), 4.87 (s, 1H), 4.83 (s, 1H), 4.50 (s, 2H), 3.83 – 3.77 (m, 4H), 3.48 (app. t, *J* = 6.4 Hz, 2H), 2.78 (app. t, *J* = 7.4 Hz, 2H), 2.49 – 2.46 (m, 2H), 2.39 – 2.24 (m, 3H), 2.18 – 2.09 (m, 3H), 1.95 (d, *J* = 4.0 Hz, 1H), 1.81 – 1.73 (m, 2H), 1.53 (s, 1H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 159.7, 145.8, 142.5, 138.6, 129.5, 128.5, 127.8, 127.7, 120.9, 114.4, 112.6, 111.6, 82.4, 77.1, 73.1, 69.9, 68.0, 55.2, 43.3, 35.5, 32.5, 27.9, 27.3, 20.9; **IR** (neat, cm⁻¹): 3445 (w), 3030 (w), 2934 (s), 2858 (m), **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₂₆H₃₃O₃ 393.2430; found, 393.2417; [α]_D²²: -2.4 (*c* 0.0033, CHCl₃).

C. Synthesis of Hydrindanes:




Synthesis of Hydrindane S18: Trimethylsilyl propyne (130 μL , 0.90 mmol, 3.3 equiv) and $\text{Ti}(\text{O}i\text{-Pr})_4$ (0.27 mL, 0.901 mmol, 3.3 equiv) in anhydrous toluene (3.0 mL) were stirred in a round bottom flask at $-78\text{ }^\circ\text{C}$. Then, $n\text{-BuLi}$ (0.72 mL, 1.80 mmol, 6.6 equiv) was added dropwise. The resulting solution was warmed to rt, then was heated in an oil bath to $50\text{ }^\circ\text{C}$ for 1 h. The reaction mixture was then cooled to rt.

In a separate flask the enyne **S10** (111 mg, 0.273 mmol, 1.0 equiv) was diluted with anhydrous toluene (0.9 mL) and cooled to $-78\text{ }^\circ\text{C}$ prior to the dropwise addition of $n\text{-BuLi}$ (0.11 mL, 0.273 mmol, 1.0 equiv). The resulting mixture was stirred for 10 min at $-78\text{ }^\circ\text{C}$, then was warmed to rt.


The solution containing the enyne was then added dropwise into the flask containing TMS-propyne, and the entire mixture was stirred overnight (18 h). Progress of the desired annulation was monitored by TLC (30% EtOAc in hexanes) and the reaction was quenched with a saturated aqueous solution of NaHCO_3 (1.5 mL) and stirred for 30 mins. The organic phase was decanted, and the aqueous phase was extracted with copious amounts of EtOAc by repeatedly rinsing the reaction flask and decanting the organic phase into a separate flask. The combined organic phase was dried over Na_2SO_4 , filtered, and concentrated *in vacuo*. The crude product was purified by flash column chromatography on a Biotage[®] Sfär Silica HC D 10 g cartridge and a gradient from 0–35% EtOAc in hexanes to afford hydrindane **S18** (82 mg, 0.158 mmol, 58%) as an orange oil.

Data for Compound S18: For NMR Spectra of **S18** see page S76. **TLC:** $R_f = 0.42$ (30% EtOAc in hexanes); **^1H NMR** (600 MHz, CDCl_3): δ 7.14 (d, $J = 8.9$ Hz, 1H), 6.76 (d, $J = 8.6$ Hz, 1H), 6.72 (s, 1H), 4.40 (app. p, $J = 6.3$ Hz, 1H), 3.79 (s, 3H), 2.75 (app. dt, $J = 14.0, 7.2$ Hz, 1H), 2.63 (m, 2H), 2.51 – 2.42 (m, 1H), 2.41 – 2.32 (m, 1H), 2.17 (d, $J = 15.9$ Hz, 1H), 2.05 – 1.94 (m, 3H), 1.89 (s, 3H), 1.38 (dd, $J = 12.0, 8.0$ Hz, 1H), 0.79 (s, 3H), 0.15 (s, 9H); **$^{13}\text{C}\{^1\text{H}\}$ NMR** (151 MHz, CDCl_3): δ 158.8, 145.3, 141.9, 140.9, 136.1, 128.8, 128.6, 122.1, 121.9, 119.8, 117.7, 117.2, 115.6, 112.5, 72.0, 55.8, 51.0, 41.5, 39.5, 38.4, 30.3, 30.0, 21.2, 19.1, 0.1.



Synthesis of Hydrindane 27: To a stirring solution of hydrindane **S18** (23 mg, 0.044 mmol, 1 equiv) at 0 °C in THF (0.9 mL) was added 1 M HCl (0.56 mL), slowly. The reaction mixture was warmed to rt and stirred for 6 h (reaction progress was monitored by TLC (30% EtOAc in hexanes)). Upon completion, the reaction mixture was diluted with EtOAc (1.5 mL) and the organic phase was separated and extracted with EtOAc (3 x 5 mL). The combined organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude material was purified by flash column chromatography on a Biotage® Sfar Silica HC D 10 g cartridge and a gradient from 0–35% EtOAc in hexanes to afford protodesilylated hydrindane **27** (10.5 mg, 0.024 mmol, 53%) as a clear oil.


Data for Compound 27: The spectral data for **27** matched previously reported data by Millham *et al.*⁶ For NMR Spectra of **27** see page S77. **TLC:** R_f = 0.35 (30% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.15 (d, *J* = 9.0 Hz, 1H), 6.77 (dd, *J* = 9.0, 3.1 Hz, 1H), 6.74 (d, *J* = 3.1 Hz, 1H), 5.42 (d, *J* = 6.0 Hz, 1H), 4.43 – 4.35 (m, 1H), 3.80 (s, 3H), 2.77 (ddd, *J* = 14.1, 8.2, 6.1 Hz, 1H), 2.67 – 2.56 (m, 2H), 2.44 – 2.31 (m, 2H), 2.12 (app. d, *J* = 16.5 Hz, 1H), 2.07 – 2.00 (m, 2H), 1.91 (dd, *J* = 17.8, 6.2 Hz, 1H), 1.82 (s, 3H), 1.39 (dd, *J* = 12.2, 7.9 Hz, 1H), 1.28 (d, *J* = 5.8 Hz, 1H), 0.87 (s, 3H); **¹³C{¹H} NMR** (151 MHz, CDCl₃): δ 158.8, 143.8, 141.9, 136.1, 132.4, 127.0, 122.2, 121.9, 120.4, 119.8, 117.7, 117.3, 115.7, 112.5, 72.0, 55.8, 51.1, 40.4, 38.0, 37.7, 30.2, 30.2, 22.3, 19.3.



Synthesis of Hydrindane 41: To a stirring solution of hydrindane **S19**⁶ (284 mg, 0.636 mmol, 1.0 equiv) at 0 °C in THF (4 mL) was slowly added 1 M HCl (4 mL). The reaction mixture was warmed to rt over 4 h. Once reaction was judged to be complete by TLC analysis (20% EtOAc in hexanes) the mixture was cooled to 0 °C and saturated aqueous NaHCO₃ (3 mL) was added. The resulting solution was further diluted with EtOAc (5 mL), the biphasic solution was separated, and the aqueous phase was extracted with EtOAc (3 x 15 mL). The combined organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage® Snap Ultra 10 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford **41** (144 mg, 0.384 mmol, 60%) as a pale-yellow oil.


Data for Compound 41: For NMR Spectra of **41** see page S94. **TLC:** R_f = 0.23 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.29 – 7.25 (m, 2H), 7.21 – 7.16 (m, 4H), 6.74 – 6.71

(m, 2H), 6.65 (s, 1H), 5.46 (d, $J = 6.14$ Hz, 1H), 4.39 – 4.36 (m, 1H), 3.80 (s, 3H), 3.54 – 3.47 (m, 2H), 2.65 (dd, $J = 17.7, 7.4$ Hz, 2H), 2.45 (app. dt, $J = 8.2, 7.6$ Hz, 1H), 2.33 – 2.31 (m, 1H), 2.23 – 2.19 (m, 2H), 2.13 (dd, $J = 16.6, 6.6$ Hz, 1H), 2.06 – 2.03 (m, 1H), 1.89 (dd, $J = 17.9, 6.4$ Hz, 1H), 1.43 (dd, $J = 8.0, 4.3$ Hz, 1H), 1.26 (m, 1H), 0.94 (s, 3H), $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 159.5, 143.8, 143.7, 140.6, 135.7, 130.3, 129.1, 128.7, 128.3, 127.2, 125.9, 122.5, 121.2, 114.7, 110.9, 71.8, 55.2, 51.2, 40.1, 39.4, 38.0, 37.7, 35.5, 31.4, 22.2; **IR** (neat, cm^{-1}): 3348 (s), 2921 (m), **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{31}\text{O}_2$ 375.2324; found, 375.2314; $[\alpha]_{589}^{21.0}$: -10.3 (c 0.210, CHCl_3).



Synthesis of Hydrindane 43: To a solution of **S19** (1.00 g, 2.24 mmol, 1.0 equiv) in THF (11 mL) at 0 °C was added NaH (270 mg, 6.72 mmol, 3 equiv), and the resulting mixture was stirred for 10 min before the addition of MeI (0.836 mL, 13.43 mmol, 6 equiv). The solution was warmed to rt and stirred overnight. When the reaction was judged to be complete by TLC analysis, the reaction mixture was cooled to 0 °C and a saturated aqueous solution of NaHCO_3 (3 mL) was added. The resulting biphasic mixture was separated, and the aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic phase was dried over Na_2SO_4 , filtered, and concentrated *in vacuo*. The crude product was purified by flash chromatography with a Biotage[®] Snap Ultra 25 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford **43** (931 mg, 2.02 mmol, 91%) as a pale-yellow oil.

Data for Compound 43: For NMR Spectra of **43** see page S95. **TLC:** $R_f = 0.50$ (20% EtOAc in hexanes); ^1H NMR (600 MHz, CDCl_3): δ 7.25 (d, $J = 7.2$ Hz, 2H), 7.17 – 7.14 (m, 4H), 6.71 (d, $J = 8.0$ Hz, 1H), 6.66 (d, $J = 7.4$ Hz, 1H), 6.58 (s, 1H), 4.02 – 3.96 (m, 1H), 3.78 (s, 3H), 3.56 (d, $J = 16.1$ Hz, 1H), 3.31 (s, 3H), 2.71 (dd, $J = 18.1, 7.7$ Hz, 1H), 2.50 – 2.45 (m, 1H), 2.38 (m, 1H), 2.32 (d, $J = 16.0$ Hz, 1H), 2.20 (m, 1H), 2.15 – 2.08 (m, 5H), 1.44 (dd, $J = 10.5, 2.8$ Hz, 1H), 0.93 (s, 3H), 0.15 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 159.5, 145.1, 143.8, 143.0, 141.0, 131.4, 129.1, 128.8, 128.3, 128.3, 125.8, 120.8, 114.3, 80.1, 57.0, 55.1, 48.0, 41.6, 38.9, 38.4, 35.6, 35.0, 31.6, 21.0, 0.2; **IR** (neat, cm^{-1}): 2947 (m), 1601 (m), **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{30}\text{H}_{40}\text{O}_2\text{SiNa}$ 483.2695; found, 483.2672; $[\alpha]_{589}^{21.0}$: $+53.0$ (c 0.605, CHCl_3).




Synthesis of Hydrindane S21: A solution of TMS-alkyne **S2** (1.50 g, 6.45 mmol, 3.3 equiv), $\text{Ti}(\text{O}i\text{-Pr})_4$ (1.9 mL, 6.45 mmol, 3.3 equiv), in anhydrous toluene (21.5 mL) was stirred in a round

bottom flask at $-78\text{ }^{\circ}\text{C}$. Then, *n*-BuLi (5 mL, 12.7 mmol, 6.4 equiv, 2.5 M in hexanes) was added dropwise. The resulting solution was warmed to rt, then was heated in an oil bath to $50\text{ }^{\circ}\text{C}$ for 1 h. The reaction mixture was then cooled to rt.

In a separate flask the enyne **S20**⁷ (506 mg, 1.96 mmol, 1.0 equiv) was diluted with anhydrous toluene (6.5 mL) and cooled to $-78\text{ }^{\circ}\text{C}$ prior to the dropwise addition of *n*-BuLi (0.78 mL, 1.96 mmol, 1.0 equiv, 2.5 M in hexanes). The resulting mixture was stirred for 10 min at $-78\text{ }^{\circ}\text{C}$, then was warmed to rt.

The solution containing the enyne was then added dropwise into the flask containing TMS-alkyne **S2**, and the entire mixture was stirred overnight (18 h). Progress of the desired annulation was monitored by TLC (30% EtOAc in hexanes) and the reaction was quenched with benzaldehyde (6.45 mmol, 3.3 equiv), which was stirred for 30 min before the addition of saturated aqueous NaHCO_3 (15 mL). The organic phase was decanted, and the aqueous phase was extracted with copious amounts of EtOAc by repeatedly rinsing the reaction flask and decanting the organic phase into a separate flask. The combined organic phase was dried over Na_2SO_4 , filtered, and concentrated *in vacuo*. The crude product was purified by flash column chromatography on a Biotage[®] Snap Ultra 25 g cartridge and a gradient from 0–40% EtOAc in hexanes to afford hydrindane **S21** (542 mg, 1.10 mmol, 56%) as a pale, yellow oil.

Data for Compound S21: For NMR Spectra of **S21** see page S101. **TLC:** $R_f = 0.19$ (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl_3): δ 7.33 – 7.31 (m, 4H), 7.29 – 7.27 (m, $J = 4.33$ Hz, 1H), 7.17 (app. t, $J = 7.8$ Hz, 1H), 6.73 (d, $J = 7.9$ Hz, 2H), 6.66 (s, 1H), 4.49 (s, 2H), 4.34 – 4.31 (m, 1H), 3.78 (s, 3H), 3.43 (td, $J = 10.0, 4.9$ Hz, 1H), 3.32 (td, $J = 6.3, 3.3$ Hz, 1H), 2.78 (ddd, $J = 6.3, 4.5, 2.4$ Hz, 1H), 2.67 – 2.58 (m, 3H), 2.49 – 2.42 (m, 2H), 2.34 – 2.31 (m, 1H), 2.15 (d, $J = 16.0$ Hz, 1H), 1.98 – 2.92 (m, 2H), 1.90 (dd, $J = 11.3, 6.3$ Hz, 1H), 1.35 (dd, $J = 7.7, 4.8$ Hz, 1H), 1.09 (d, $J = 6.4$ Hz, 1H), 0.74 (s, 3H), 0.16 (s, 9H); **¹³C{¹H} NMR** (150 MHz, CDCl_3): δ 159.3, 145.3, 143.3, 141.8, 138.3, 131.4, 129.0, 128.2, 127.9, 127.4, 127.3, 121.0, 114.6, 110.8, 72.9, 71.6, 70.8, 55.0, 50.8, 41.3, 39.0, 38.3, 35.3, 32.6, 31.2, 21.0; **IR** (neat, cm^{-1}): 3398 (s), 2921 (m), 1601 (m), **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{31}\text{H}_{43}\text{O}_3\text{Si}$ 491.2981; found, 491.2975; $[\alpha]_{589}^{20.8}$: -1.4 (c 0.15, CHCl_3).




Synthesis of Hydrindane S22: A solution of TMS-alkyne **S4** (0.515 mL, 2.55 mmol, 3.3 equiv), $\text{Ti}(\text{O}i\text{-Pr})_4$ (0.755 mL, 2.55 mmol, 3.3 equiv), in anhydrous toluene (8.5 mL) was stirred in a round bottom flask at $-78\text{ }^{\circ}\text{C}$. Then, *n*-BuLi (2 mL, 5.03 mmol, 6.5 equiv, 2.5 M in hexanes) was added dropwise. The resulting solution was warmed to rt, then was heated in an oil bath to $50\text{ }^{\circ}\text{C}$ for 1 h. The reaction mixture was then cooled to rt.

In a separate flask the enyne **S20**⁷ (200 mg, 0.774 mmol, 1.0 equiv) was diluted with anhydrous toluene (2.6 mL) and cooled to $-78\text{ }^{\circ}\text{C}$ prior to the dropwise addition of *n*-BuLi (0.31 mL, 0.774 mmol, 1.0 equiv, 2.5 M in hexanes). The resulting mixture was stirred for 10 min at $-78\text{ }^{\circ}\text{C}$, then was warmed to rt.

The solution containing the enyne was then added dropwise into the flask containing TMS-alkyne **S4**, and the entire mixture was stirred overnight (18 h). Progress of the desired annulation was monitored by TLC (30% EtOAc in hexanes) and the reaction was quenched with benzaldehyde (270 μL , 2.55 mmol, 3.3 equiv), which was stirred for 30 min before the addition of saturated aqueous NaHCO_3 (5 mL). The organic phase was decanted, and the aqueous phase was extracted with copious amounts of EtOAc by repeatedly rinsing the reaction flask and decanting the organic phase into a separate flask. The combined organic phase was dried over Na_2SO_4 , filtered, and concentrated *in vacuo*. The crude product was purified by flash column chromatography on a Biotage[®] Snap Ultra 25 g cartridge and a gradient from 0–25% EtOAc in hexanes to afford hydrindane **S22** (161 mg, 0.390 mmol, 51%) as a pale, yellow oil.

Data for Compound S22: For NMR Spectra of **S22** see page S104. **TLC:** $R_f = 0.13$ (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl_3): δ 7.18 (app. t, $J = 7.8$ Hz, 1H), 6.76 – 6.72 (m, 2H), 6.67 (s, 1H), 4.38 – 4.31 (m, 1H), 3.79 (s, 3H), 2.72 – 2.62 (m, 2H), 2.50 – 2.43 (m, 1H), 2.43 – 2.31 (m, 3H), 2.21 – 2.17 (m, 1H), 2.13 (d, $J = 16.0$ Hz, 1H), 2.01 – 1.91 (m, 3H), 1.41 – 1.31 (m, 4H), 1.21 – 1.13 (m, 1H), 1.10 (d, $J = 6.4$ Hz, 1H), 0.92 (t, $J = 6.7$ Hz, 3H), 0.79 (s, 3H), 0.16 (s, 9H); **¹³C{¹H} NMR** (150 MHz, CDCl_3): δ 146.9, 145.2, 143.9, 129.3, 128.5, 128.4, 121.3, 114.8, 111.1, 72.0, 55.3, 51.2, 41.5, 39.4, 38.6, 35.7, 33.4, 32.5, 31.6, 23.2, 21.4, 14.2, 0.4; **IR** (neat, cm^{-1}): 3384 (m, br), 2952 (s), 2858 (s), 1740 (w); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{41}\text{O}_2\text{Si}$ 413.2876; found, 413.2870; $[\alpha]_{589}^{22.0}$: -7.2 (c 0.0025, CHCl_3).




Synthesis of Hydrindane S24: A solution of TMS-alkyne **S23** (521 mg, 2.55 mmol, 3.3 equiv), Ti(Oi-Pr)_4 (0.755 mL, 2.55 mmol, 3.3 equiv), in anhydrous toluene (8.5 mL) was stirred in a round bottom flask at $-78\text{ }^{\circ}\text{C}$. Then, *n*-BuLi (2 mL, 5.03 mmol, 6.5 equiv, 2.5 M in hexanes) was added dropwise. The resulting solution was warmed to rt, then was heated in an oil bath to $50\text{ }^{\circ}\text{C}$ for 1 h. The reaction mixture was then cooled to rt.

In a separate flask the enyne **S20**⁷ (200 mg, 0.774 mmol, 1.0 equiv) was diluted with anhydrous toluene (2.6 mL) and cooled to $-78\text{ }^{\circ}\text{C}$ prior to the dropwise addition of *n*-BuLi (0.31 mL, 0.774 mmol, 1.0 equiv, 2.5 M in hexanes). The resulting mixture was stirred for 10 min at $-78\text{ }^{\circ}\text{C}$, then was warmed to rt.

The solution containing the enyne was then added dropwise into the flask containing TMS-alkyne **S23**, and the entire mixture was stirred overnight (18 h). Progress of the desired annulation was monitored by TLC (30% EtOAc in hexanes) and the reaction was quenched with benzaldehyde (260 μ L, 2.55 mmol, 3.3 equiv), which was stirred for 30 min before the addition of saturated aqueous NaHCO₃ (15 mL). The organic phase was decanted, and the aqueous phase was extracted with copious amounts of EtOAc by repeatedly rinsing the reaction flask and decanting the organic phase into a separate flask. The combined organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude product was purified by flash column chromatography on a Biotage[®] Snap Ultra 25 g cartridge and a gradient from 0–40% EtOAc in hexanes to afford hydrindane **S24** (224 mg, 0.484 mmol, 63%) as a pale, yellow oil.

Data for Compound S24: For NMR Spectra of **S24** see page S107. **TLC:** R_f = 0.27 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.10 (app. t, J = 7.8 Hz, 2H), 6.95 (s, 1H), 6.85 (s, 2H), 6.70 – 6.64 (m, 1H), 6.51 (d, J = 7.5 Hz, 1H), 6.37 (d, J = 2.5 Hz, 1H), 4.48 – 4.40 (m, 1H), 3.83 (d, J = 1.1 Hz, 3H), 3.73 (d, J = 1.1 Hz, 3H), 2.69 (dd, J = 17.9, 7.6 Hz, 1H), 2.38 – 2.30 (m, 2H), 2.25 – 2.21 (m, 2H), 2.17 (d, J = 15.8 Hz, 2H), 2.14 – 2.08 (m, 3H), 2.05 – 2.00 (m, 1H), 1.49 (dd, J = 12.3, 7.9 Hz, 1H), 1.33 (br, 1H), 0.95 (s, 3H), -0.23 (s, 9H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 159.4, 158.5, 147.4, 144.6, 143.9, 134.7, 131.7, 129.0, 128.6, 121.0, 114.1, 111.1, 72.0, 55.2, 55.1, 51.1, 41.1, 39.5, 38.3, 35.3, 32.3, 21.3, 21.2, 0.6; **IR** (neat, cm⁻¹): 3366 (s), 2950 (m); **HRMS** (ESI-TOF) (m/z): [M+H]⁺ calcd for C₂₉H₃₉O₃Si 463.2668; found, 463.2651; [α]_D^{21.6}: +50.2 (c 0.145, CHCl₃).




Synthesis of Hydrindane S25: A solution of TMS propyne (0.333 mL, 2.25 mmol, 3.3 equiv), Ti(Oi-Pr)₄ (0.666 mL, 2.25 mmol, 3.3 equiv), in anhydrous toluene (7.5 mL) was stirred in a round bottom flask at -78 °C. Then, *n*-BuLi (1.95 mL, 4.875 mmol, 6.4 equiv, 2.5 M in hexanes) was added dropwise. The resulting solution was warmed to rt, then was heated in an oil bath to 50 °C for 1 h. The reaction mixture was then cooled to rt.

In a separate flask the enyne **S14** (250 mg, 0.75 mmol, 1.0 equiv) was diluted with anhydrous toluene (2.5 mL) and cooled to -78 °C prior to the dropwise addition of *n*-BuLi (0.3 mL, 0.967 mmol, 1.0 equiv, 2.5 M in hexanes). The resulting mixture was stirred for 10 min at -78 °C, then was warmed to rt.

The solution containing the enyne was then added dropwise into the flask containing TMS-alkyne **S2**, and the entire mixture was stirred overnight (18 h). Progress of the desired annulation was monitored by TLC (30% EtOAc in hexanes) and the reaction was quenched with benzaldehyde (0.076 mL, 0.75 mmol, 3.3 equiv), which was stirred for 30 min before the addition of saturated aqueous NaHCO₃ (8 mL). The organic phase was decanted, and the aqueous phase was extracted with copious amounts of EtOAc by repeatedly rinsing the reaction flask and decanting the organic

phase into a separate flask. The combined organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude product was purified by flash column chromatography on a Biotage[®] Snap Ultra 25 g cartridge and a gradient from 0–40% EtOAc in hexanes to afford hydrindane **S25** (176 mg, 0.394 mmol, 52%) as a pale, yellow oil.

Data for Compound S25: For NMR Spectra of **S25** see page S110. **TLC:** R_f = 0.24 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.24 (app. t, *J* = 7.42 Hz, 2H), 7.21 – 7.17 (m, 2H), 7.05 (d, *J* = 7.41 Hz, 2H), 6.75 (dd, *J* = 7.5, 8.2 Hz, 2H), 6.70 (s, 1H), 4.12 – 4.06 (m, 1H), 3.79 (s, 3H), 2.72 – 2.67 (m, 1H), 2.59 – 2.51 (m, 3H), 2.43 – 2.35 (m, 3H), 2.31 – 2.25 (m, 2H), 2.03 (s, 2H), 1.96 (dd, *J* = 17.4, 5.3 Hz, 2H), 1.88 (d, *J* = 16.7 Hz, 1H), 1.21 (dd, *J* = 6.9, 6.1 Hz, 1H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 159.5, 143.8, 143.6, 142.1, 139.2, 130.3, 130.1, 129.2, 128.9, 127.8, 125.9, 121.1, 114.7, 110.9, 71.7, 55.1, 47.3, 44.4, 39.5, 39.2, 38.5, 35.6, 31.6, 19.3, 0.3; **IR** (neat, cm⁻¹): 3349 (s), 2948 (m); **HRMS** (ESI-TOF) (*m/z*): [M+Na]⁺ calcd for C₂₉H₃₈O₂SiNa 469.2641; found, 469.2531; [α]_D^{20.8}: –100.6 (*c* 0.51, CHCl₃).




Synthesis of Hydrindane S26: A solution of TMS-alkyne **S2** (335 mg, 1.44 mmol, 3.3 equiv), Ti(O*i*-Pr)₄ (0.426 mL, 1.44 mmol, 3.3 equiv), in anhydrous toluene (6 mL) was stirred in a round bottom flask at –78 °C. Then, *n*-BuLi (1.1 mL, 2.84 mmol, 6.4 equiv, 2.5 M in hexanes) was added dropwise. The resulting solution was warmed to rt, then was heated in an oil bath to 50 °C for 1 h. The reaction mixture was then cooled to rt.

In a separate flask the enyne **S14** (146 mg, 0.436 mmol, 1.0 equiv) was diluted with anhydrous toluene (1.5 mL) and cooled to –78 °C prior to the dropwise addition of *n*-BuLi (0.175 mL, 0.436 mmol, 1.0 equiv, 2.5 M in hexanes). The resulting mixture was stirred for 10 min at –78 °C, then was warmed to rt.

The solution containing the enyne was then added dropwise into the flask containing TMS-alkyne **S2**, and the entire mixture was stirred overnight (18 h). Progress of the desired annulation was monitored by TLC (30% EtOAc in hexanes) and the reaction was quenched with benzaldehyde (1.44 mmol, 3.3 equiv), which was stirred for 30 min before the addition of saturated aqueous NaHCO₃ (5 mL). The organic phase was decanted, and the aqueous phase was extracted with copious amounts of EtOAc by repeatedly rinsing the reaction flask and decanting the organic phase into a separate flask. The combined organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude product was purified by flash column chromatography on a Biotage[®] Snap Ultra 25 g cartridge and a gradient from 0–40% EtOAc in hexanes to afford hydrindane **S26** (140 mg, 0.244 mmol, 56%) as a pale, yellow oil.

Data for Compound S26: For NMR Spectra of **S26** see page S113. **TLC:** R_f = 0.19 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.34 – 7.27 (m, 5H), 7.20 – 7.15 (m, 4H), 6.99 (d, *J*

= 7.1 Hz, 2H), 6.74 (dd, $J = 8.2, 2.9$ Hz, 2H), 6.67 (s, 1H), 4.54 – 4.48 (m, 2H), 3.90 (s, 1H), 3.77 (s, 3H), 3.55 (td, $J = 5.0, 4.5$ Hz, 1H), 3.42 (td, $J = 6.4, 2.9$ Hz, 1H), 2.88 – 2.84 (m, 1H), 2.74 – 2.69 (m, 2H), 2.62 (d, $J = 13.0$ Hz, 1H), 2.56 – 2.48 (m, 2H), 2.41 – 2.37 (m, 1H), 2.29 – 2.17 (m, 4H), 1.89 (d, $J = 16.7$ Hz, 1H), 1.82 (dd, $J = 17.4, 5.2$ Hz, 1H), 1.20 (dd, $J = 6.6, 6.5$ Hz, 1H), 0.91 (s, 1H), 0.21 (s, 9H); $^{13}\text{C}\{\text{1H}\}$ NMR (150 MHz, CDCl_3): δ 159.0, 144.4, 142.9, 142.7, 138.8, 131.9, 129.6, 128.6, 128.5, 127.8, 127.7, 127.3, 127.2, 127.0, 125.4, 120.7, 114.3, 110.5, 72.6, 71.0, 70.6, 54.6, 46.7, 43.8, 39.4, 39.1, 38.3, 34.9, 32.8, 31.0, 0.0; IR (neat, cm^{-1}): 3397 (s), 3060 (m), 3027 (m), 2949 (m), 2856 (m); HRMS (ESI-TOF) (m/z): $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{37}\text{H}_{46}\text{O}_3\text{SiNa}$ 589.3216; found, 589.3116; $[\alpha]_{589}^{21.5}$: -57.2 (c 0.15, CHCl_3).




Synthesis of Hydrindane S27: A solution of TMS-propyne (707 mg, 6.30 mmol, 3.3 equiv), $\text{Ti}(\text{O}i\text{-Pr})_4$ (1.87 mL, 6.30 mmol, 3.3 equiv), in anhydrous toluene (42 mL) was stirred in a round bottom flask at $-78\text{ }^\circ\text{C}$. Then, $n\text{-BuLi}$ (4.89 mL, 12.2 mmol, 6.4 equiv, 2.5 M in hexanes) was added dropwise. The resulting solution was warmed to rt, then was heated in an oil bath to $50\text{ }^\circ\text{C}$ for 1 h. The reaction mixture was then cooled to rt.

In a separate flask the enyne **S17** (750 mg, 1.91 mmol, 1.0 equiv) was diluted with anhydrous toluene (6.4 mL) and cooled to $-78\text{ }^\circ\text{C}$ prior to the dropwise addition of $n\text{-BuLi}$ (0.764 mL, 1.91 mmol, 1.0 equiv, 2.5 M in hexanes). The resulting mixture was stirred for 10 min at $-78\text{ }^\circ\text{C}$, then was warmed to rt.

The solution containing the enyne was then added dropwise into the flask containing TMS-alkyne TMS-propyne, and the entire mixture was stirred overnight (18 h). Progress of the desired annulation was monitored by TLC (30% EtOAc in hexanes) and the reaction was quenched with benzaldehyde (0.640 mL, 6.3 mmol, 3.3 equiv), which was stirred for 30 min before the addition of saturated aqueous NaHCO_3 (10 mL). The organic phase was decanted, and the aqueous phase was extracted with copious amounts of EtOAc by repeatedly rinsing the reaction flask and decanting the organic phase into a separate flask. The combined organic phase was dried over Na_2SO_4 , filtered, and concentrated *in vacuo*. The crude product was purified by flash column chromatography on a Biotage[®] Snap Ultra 25 g cartridge and a gradient from 0–40% EtOAc in hexanes to afford hydrindane **S27** (622 mg, 1.23 mmol, 64%) as a pale, yellow oil.

Data for Compound S27: For NMR Spectra of **S27** see page S116. TLC: $R_f = 0.10$ (20% EtOAc in hexanes); ^1H NMR (600 MHz, CDCl_3): δ 7.35 – 7.29 (m, 5H), 7.18 (app. t, $J = 7.8$ Hz, 1H), 6.75 – 6.72 (m, 2H), 6.67 (s, 1H), 4.46 (s, 2H), 4.32 – 4.27 (m, 1H), 3.78 (s, 3H), 3.41 – 3.30 (m, 2H), 2.73 – 2.60 (m, 1H), 2.60 – 2.43 (m, 3H), 2.39 – 2.29 (m, 2H), 2.13 (dd, $J = 12.8, 5.9$ Hz, 1H), 2.07 – 2.00 (m, 1H), 1.92 (s, 3H), 1.87 (d, $J = 16.5$ Hz, 1H), 1.53 (s, 1H), 1.48 – 1.38 (m, 2H), 1.38 – 1.31 (m, 1H), 1.31 – 1.23 (m, 1H), 1.10 – 1.01 (m, 2H), 0.15 (s, 9H); $^{13}\text{C}\{\text{1H}\}$ NMR (150 MHz, CDCl_3): δ 159.6, 144.8, 143.8, 142.1, 138.7, 129.7, 129.3, 128.5, 128.4, 127.7, 127.6,

121.3, 114.8, 111.1, 72.9, 72.3, 71.1, 55.3, 47.6, 42.5, 38.8, 38.3, 35.8, 31.5, 29.2, 25.7, 19.2, 0.3; **IR** (neat, cm^{-1}): 3398 (w), 2947 (s); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{32}\text{H}_{45}\text{O}_3\text{Si}$ 505.3138; found, 505.3145; $[\alpha]_{589}^{22.3}$: -34.7 (c 0.002, CHCl_3).




Synthesis of Hydrindane S29: A solution of TMS-alkyne **S28** (1.19 g, 6.30 mmol, 3.3 equiv), $\text{Ti}(\text{O}i\text{-Pr})_4$ (1.87 mL, 6.30 mmol, 3.3 equiv), in anhydrous toluene (42 mL) was stirred in a round bottom flask at $-78\text{ }^\circ\text{C}$. Then, $n\text{-BuLi}$ (4.89 mL, 12.2 mmol, 6.4 equiv, 2.5 M in hexanes) was added dropwise. The resulting solution was warmed to rt, then was heated in an oil bath to $50\text{ }^\circ\text{C}$ for 1 h. The reaction mixture was then cooled to rt.

In a separate flask the enyne **S17** (750 mg, 1.91 mmol, 1.0 equiv) was diluted with anhydrous toluene (6.4 mL) and cooled to $-78\text{ }^\circ\text{C}$ prior to the dropwise addition of $n\text{-BuLi}$ (0.764 mL, 1.91 mmol, 1.0 equiv, 2.5 M in hexanes). The resulting mixture was stirred for 10 min at $-78\text{ }^\circ\text{C}$, then was warmed to rt.

The solution containing the enyne was then added dropwise into the flask containing TMS-alkyne **S28**, and the entire mixture was stirred overnight (18 h). Progress of the desired annulation was monitored by TLC (30% EtOAc in hexanes) and the reaction was quenched with benzaldehyde (0.64 mL, 6.3 mmol, 3.3 equiv), which was stirred for 30 min before the addition of saturated aqueous NaHCO_3 (15 mL). The organic phase was decanted, and the aqueous phase was extracted with copious amounts of EtOAc by repeatedly rinsing the reaction flask and decanting the organic phase into a separate flask. The combined organic phase was dried over Na_2SO_4 , filtered, and concentrated *in vacuo*. The crude product was purified by flash column chromatography on a Biotage[®] Snap Ultra 25 g cartridge and a gradient from 0–40% EtOAc in hexanes to afford hydrindane **S29** (699 mg, 1.20 mmol, 63%) as a pale, yellow oil.

Data for Compound S29: For NMR Spectra of **S29** see page S119. **TLC:** $R_f = 0.15$ (30% EtOAc in hexanes); **^1H NMR** (600 MHz, CDCl_3): δ 7.35 – 7.11 (m, 12H), 6.72 (d, $J = 8.0$ Hz, 1H), 6.66 (d, $J = 7.4$ Hz, 1H), 6.58 (s, 1H), 4.50 (s, 2H), 4.34 – 4.27 (m, 1H), 3.82 (d, $J = 16.3$ Hz, 1H), 3.78 (s, 3H), 3.59 (d, $J = 16.0$ Hz, 1H), 3.40 (app. t, $J = 5.9$ Hz, 1H), 2.59 – 2.52 (m, 2H), 2.45 (d, $J = 16.4$ Hz, 1H), 2.40 – 2.33 (m, 1H), 2.29 – 2.23 (m, 1H), 2.20 – 2.15 (m, 2H), 2.07 – 1.99 (m, 2H), 1.55 (s, 1H), 1.53 – 1.48 (m, 1H), 1.47 – 1.43 (m, 2H), 1.35 (dd, $J = 13.2, 5.9$ Hz, 1H), 1.29 – 1.25 (m, 1H), 1.08 (d, $J = 5.5$ Hz, 1H), 0.17 (s, 9H); **$^{13}\text{C}\{^1\text{H}\}$ NMR** (150 MHz, CDCl_3): δ 159.6, 146.0, 144.1, 143.8, 140.9, 138.8, 132.1, 129.3, 129.3, 128.5, 128.5, 128.4, 128.3, 127.7, 127.6, 127.2, 127.1, 126.0, 121.2, 114.7, 111.1, 73.1, 72.1, 71.1, 55.3, 47.8, 42.4, 39.4, 39.3, 38.8, 35.8, 31.5, 29.1, 25.8, 0.7; **IR** (neat, cm^{-1}): 3394 (b), 2946 (s); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{38}\text{H}_{49}\text{O}_3\text{Si}$ 581.3451; found, 581.3443; $[\alpha]_{589}^{22.3}$: -7.3 (c 0.0005, CHCl_3).

D. Initial studies on C9,C13 *Anti/Syn* Selective Reactions and Oxidative Shift






Synthesis of Tetracycle 21: To a stirring solution of *o,o'*-dihydroxybiphenyl (0.12 g, 0.64 mmol, 5.4 equiv) in CH₂Cl₂ (6 mL) at -78 °C was added a solution of SnCl₄ (1.0 M in CH₂Cl₂, 0.60 mL, 0.60 mmol, 5.0 equiv) dropwise via syringe. The resulting mixture was stirred for 30 min at -78 °C, and then a solution of **20**⁷ (47 mg, 0.12 mmol, 1.0 equiv) in 2 mL CH₂Cl₂ was added dropwise via syringe. The resulting mixture was stirred for 1.5 h at -78 °C, and then warmed to rt over 9 min. At this point, the reaction was judged to be complete by TLC analysis. The reaction was quenched with a saturated solution of NaHCO₃, and then further diluted with CH₂Cl₂. The organic phase was separated, and the aqueous phase was extracted with CH₂Cl₂. The combined organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Subsequent purification by SiO₂ flash column chromatography afforded **21** and **S30** as an amorphous white solid (21 mg, 0.066 mmol, 55% combined yield).

Data for Compound 21: For NMR Spectra of **21** see page S78. ¹H NMR (600 MHz, CDCl₃) δ 7.14 (d, *J* = 8.6 Hz, 1H), 6.76 (d, *J* = 8.7 Hz, 1H), 4.15 – 4.11 (m, 1H), 3.80 (s, 3H), 3.33 (s, 3H), 2.95 – 2.88 (m, 1H), 2.77 (ddd, *J* = 16.9, 8.8, 1.6 Hz, 1H), 2.55 – 2.46 (m, 2H), 2.38 – 2.32 (m, 2H), 2.15 (dd, *J* = 11.7, 6.7 Hz, 1H), 2.12 – 2.07 (m, 4H), 1.83 – 1.76 (m, 1H), 1.72 – 1.68 (m, 2H), 1.36 – 1.30 (m, 4H), 0.88 (s, 3H); ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 155.0, 140.5, 136.0, 135.7, 131.5, 124.1, 123.7, 108.7, 80.4, 56.9, 55.7, 48.7, 41.2, 38.3, 34.9, 34.2, 33.5, 31.5, 29.6, 25.8, 24.7, 11.5; IR (thin film, cm⁻¹): 2933, 2831; HRMS (ESI-TOF): calculated for C₂₂H₃₁O₂ [M+H]⁺ 327.2324, found 327.2315. [α]_D^{22.3}: -203.4 (*c* 0.010, CHCl₃).

Data for Compound S30: For spectral data of **S30** see Kim et al.⁷


^1H NMR (600 MHz, CDCl_3) of crude material containing **21** and **S30**





Synthesis of Tetracycle 22: To a solution of (*R*)-BINOL (55 mg, 0.192 mmol, 1.2 equiv) in CH₂Cl₂ (1.5 mL) at $-78\text{ }^{\circ}\text{C}$ was added SnCl₄ (0.166 mL, 1.0 equiv, 1.0 M in CH₂Cl₂) and the resulting mixture was stirred for 30 min at $-78\text{ }^{\circ}\text{C}$ before the addition of **17**⁷ (62 mg, 0.160 mmol, 1.0 equiv) in CH₂Cl₂ (1.5 mL). The reaction mixture was stirred for 2 h at $-78\text{ }^{\circ}\text{C}$ before being warmed to rt. After stirring for an additional 1 h, the reaction was quenched with saturated aqueous NH₄Cl (2 mL). The biphasic solution was stirred for 1 h before being transferred to a separatory funnel where the phases were separated. The aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL) and the combined organic phase was washed with 5 mol% NaOH (3 mL), dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting crude product was purified by flash chromatography with a Biotage® Snap Ultra 25 g column and a gradient from 0-5% EtOAc in hexanes with 10% CH₂Cl₂ as an additive to afford **22** (25 mg, 0.096 mmol, 50%) as a white foam.

Data for Compound 22: For and NMR Spectra of **22** see page S79. **TLC:** R_f = 0.30 (10% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.22 (d, *J* = 8.7 Hz, 1H), 6.76 (dd, *J* = 8.4, 2.6 Hz, 1H), 6.59 (d, *J* = 2.3 Hz, 1H), 4.16 – 4.10 (m, 1H) 3.78 (s, 3H), 3.34 (s, 3H), 2.91 – 2.85 (m, 1H), 2.81 – 2.68 (m, 2H), 2.46 – 2.41 (m, 1H), 2.39 – 2.30 (m, 2H), 2.16 (dd, *J* = 11.7, 6.7 Hz, 1H), 2.10 – 2.07 (m, 1H), 1.88 – 1.81 (m, 1H), 1.74 – 1.69 (m, 2H), 1.14 – 1.13 (m, 4H), 0.90 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 157.1, 140.2, 137.3, 136.1, 131.7, 127.2, 113.1, 112.5, 80.3, 56.9, 55.3, 48.7, 41.2, 38.1, 34.4, 33.3, 32.3, 31.3, 29.8, 25.8, 25.0; **IR** (neat, cm⁻¹): 3391 (s), 2931 (s), 2833 (m), 1608 (m); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₂₁H₂₉O₂ 313.2168; found, 313.2165; [α]_D^{22,2}: +135.9 (c 0.002, CHCl₃).






Synthesis of Tetracycles **23 and **22**:** To a solution of (*S*)-BINOL (16 g, 56mmol, 1.2 equiv) in CH₂Cl₂ (280 mL) at $-78\text{ }^\circ\text{C}$ was added SnCl₄ (0.166 mL, 1.0 equiv, 1.0 M in CH₂Cl₂) and the resulting mixture was stirred for 30 min at $-78\text{ }^\circ\text{C}$ before the addition of **17** (17 g, 46 mmol, 1.0 equiv) in 230 mL CH₂Cl₂. The reaction mixture was the stirred for 2 h at $-78\text{ }^\circ\text{C}$ before being warmed to rt. After stirring for an additional 1 h, the reaction was quenched with saturated aqueous NH₄Cl (500 mL). The biphasic solution was stirred for 1 h before being transferred to a separatory funnel where the phases were separated. The aqueous phase was extracted with CH₂Cl₂ (3 x 300 mL) and the combined organic phase was washed with 5 mol% NaOH (500 mL), dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude product was obtained as a 1.3:1 mixture of **23** and **22** (8.35 g of **23** and **22**, 61% combined yield). A subsequent purification by SiO₂ flash column chromatography with a gradient from 0-5% EtOAc in hexanes with 10% CH₂Cl₂ as an additive afforded **23** (5.4 g of **23**, 39% isolated yield,) as yellow solid.

Data for Compound **22:** For spectral data of **22** please see previous page.

Data for Compound **23:** For NMR Spectra of **23** see page S80. ¹H NMR (600 MHz, CDCl₃) δ 7.25 (d, *J* = 8.7 Hz, 1H), 6.72 (dd, *J* = 8.7, 2.9 Hz, 1H), 6.57 (d, *J* = 2.7 Hz, 1H), 4.62 – 4.48 (m, 1H), 3.77 (s, 3H), 2.90 – 2.81 (m, 3H), 2.46 (app. dt, *J* = 13.3, 4.5 Hz, 1H), 2.42 – 2.34 (m, 1H), 2.29 (dd, *J* = 16.7, 5.1 Hz, 1H), 2.23 (ddd, *J* = 14.3, 5.6, 3.5 Hz, 1H), 2.02 (dd, *J* = 12.1, 6.5 Hz, 1H), 1.91 (ddd, *J* = 14.7, 12.3, 3.6 Hz, 1H), 1.57 (ddd, *J* = 12.9, 5.6, 3.5 Hz, 1H), 1.39 (s, 1H), 1.33 (s, 3H), 1.30 – 1.23 (m, 2H), 1.05 (s, 3H); ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 157.3, 138.9, 138.6, 137.1, 133.6, 126.4, 113.6, 112.1, 71.1, 55.3, 51.5, 41.3, 39.1, 38.1, 34.4, 34.2, 33.0, 31.9, 25.9, 24.9; IR (thin film, cm⁻¹): 3320, 2954, 2912, 2846, 1598; HRMS (ESI-TOF): calculated for C₂₀H₂₇O₂ [M+H]⁺ 299.2013, found 299.2; [α]_D^{22.2}: -117.2 (*c* 0.0086, CHCl₃).


^1H NMR (600 MHz, CDCl_3) of crude material containing **22** and **23**






Synthesis of Hydrindane S31: To a solution of **17**⁷ (586 mg, 1.58 mmol, 1 equiv) in THF (8 mL) at 0 °C was added NaH (190 mg, 4.74 mmol, 3 equiv), and the resulting mixture was stirred for 10 min before the addition of MeI (0.590 mL, 9.48 mmol, 6 equiv). The mixture was warmed to rt and stirred overnight. The reaction was quenched with H₂O (12 mL), the phases were separated, and the aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude product was purified by flash chromatography with a Biotage® Snap Ultra 25 g column and a gradient from 1–5% EtOAc in hexanes to afford **S31** (292 mg, 0.788 mmol, 50%) as a yellow oil.

Data for Compound S31: For NMR Spectra of **S31** see page S81. **TLC:** R_f = 0.41 (10% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.19 – 7.17 (m, 1H), 6.77 (d, *J* = 7.7 Hz, 1H), 6.73 (dd, *J* = 8.2, 2.5 Hz, 1H), 6.72 – 6.70 (m, 1H), 3.98 (app. p, *J* = 7.5 Hz, 1H), 3.79 (s, 3H), 3.31 (s, 3H), 2.69 (dd, *J* = 18.0, 8.1 Hz, 1H), 2.63 – 2.51 (m, 2H), 2.45 – 2.38 (m, 1H), 2.37 – 2.30 (m, 1H), 2.21 – 2.13 (m, 2H), 2.07 – 2.02 (m, 2H), 1.93 (d, *J* = 15.9 Hz, 1H), 1.90 (d, *J* = 2.5 Hz, 3H), 1.39 (dd, *J* = 11.7, 8.4 Hz, 1H), 0.80 (s, 3H), 0.15 (s, 9H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 159.7, 144.0, 141.2, 129.3, 128.0, 121.2, 121.1, 114.6, 111.1, 80.4, 57.1, 55.3, 47.8, 41.4, 35.8, 35.7, 35.0, 31.7, 21.2, 21.0, 19.1, 0.1; **IR** (neat, cm⁻¹): 2949 (s), 2832 (m), 1739 (m); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₂₄H₃₇O₂Si 385.2563; found, 385.2551; [α]_D²²: +30.1 (*c* 0.001, CHCl₃).



Synthesis of Deuterated Hydrindane 24: To a solution of hydrindane **S31**⁶ (64.9 mg, 0.0169 mmol, 1.0 equiv) at 0 °C in THF (1 mL) was slowly added 2M DCl (1 mL). The reaction mixture was warmed to rt and stirred over 20 h, then cooled to 0 °C and quenched with the addition of D₂O (2 mL). The biphasic solution was separated, and the aqueous phase was extracted with EtOAc (3 x 5 mL). The combined organic phases were dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage® Snap Ultra 10 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford **24** (22.1 mg, 0.0705 mmol, 42%) as a pale-yellow oil.


Data for Compound 24: For NMR Spectra of **24** see page S82. **TLC:** R_f = 0.40 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.19 (app. t, *J* = 7.7 Hz, 1H), 6.78 (d, *J* = 7.3 Hz, 1H), 6.74 (d, *J* = 8.4 Hz, 1H), 6.72 (s, 1H), 3.99 (app. p, *J* = 7.4 Hz, 1H), 3.80 (s, 3H), 3.30 (s, 3H), 2.66 (dd, *J* = 18.3, 7.7 Hz, 1H), 2.62 – 2.53 (m, 2H), 2.40 – 2.29 (m, 2H), 2.15 – 2.01 (m, 4H), 1.82 (s, 3H), 1.41 (app. t, *J* = 10.4 Hz, 1H), 0.88 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 159.6, 144.0, 142.3, 132.6, 129.3, 127.7, 121.1, 114.6, 111.1, 80.4, 57.0, 55.3, 47.8, 40.0, 37.5, 35.6, 34.6, 31.8, 22.2, 19.3; **IR** (neat, cm⁻¹): 2944 (s), 2819 (m), 1737 (w); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₂₁H₂₈O₂D 314.2230; found, 314.2221; [α]_D^{21.3}: +54.0 (*c* 0.265, CHCl₃).




Synthesis of Tetracycles 25 and 26: To a solution of (*S*)-BINOL (39.0 mg, 0.136 mmol, 1.2 equiv) in CH₂Cl₂ (1.3 mL) at –78 °C was added SnCl₄ (0.114 mL, 0.114 mmol, 1.0 equiv, 1.0 M in CH₂Cl₂) and the resulting mixture was stirred for 30 min at –78 °C before the addition of **24** (35.6 mg, 0.114 mmol, 1.0 equiv) in CH₂Cl₂ (1.5 mL). The reaction mixture was stirred for 1 h at –78 °C before being warmed to rt. After stirring for an additional 1 h, the reaction was quenched with saturated aqueous NH₄Cl (2 mL). The biphasic solution was stirred for 1 h before being transferred to a separatory funnel where the phases were separated. The aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL) and the combined organic phase was washed with 3 M NaOH (1 mL), dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting crude material containing a 3:1 mixture of C₉ diastereomers was purified by flash chromatography with a Biotage® Snap Ultra 5 g column and a gradient from 0-5% EtOAc in hexanes with 10% CH₂Cl₂ as an additive to afford a mixture of tetracycles **25** and **26** (18.1 mg, 0.0577 mmol, 51% combined

yield) as a white foam. The mixture was purified by HPLC with a gradient from 0-15% EtOAc in hexanes to afford the isolated diastereomers **25** and **26** as white foams.



Data for Compound 25: For NMR Spectra of **25** see page S83. **TLC:** $R_f = 0.45$ (10% EtOAc, 10% CH_2Cl_2 in hexanes); **^1H NMR** (600 MHz, CDCl_3): δ 7.20 (d, $J = 8.8$ Hz, 1H), 6.75 (dd, $J = 8.8, 2.9$ Hz, 1H), 6.58 (d, $J = 2.6$ Hz, 1H), 4.15 – 4.10 (m, 1H), 3.77 (s, 3H), 3.33 (s, 3H), 2.87 (ddd, $J = 16.1, 5.9, 2.6$ Hz, 1H), 2.79 – 2.68 (m, 2H), 2.42 (ddd, $J = 13.9, 8.1, 3.3$ Hz, 1H), 2.38 – 2.29 (m, 2H), 2.15 (dd, $J = 11.7, 6.6$ Hz, 1H), 2.06 (app t, $J = 2.6$ Hz, 1H), 1.71 – 1.68 (m, 2H), 1.37 – 1.31 (m, 4H), 0.91 (s, 3H); **$^{13}\text{C}\{^1\text{H}\}$ NMR** (150 MHz, CDCl_3): δ 156.9, 140.1, 137.2, 136.0, 131.5, 127.1, 112.9, 112.3, 80.3, 56.8, 55.1, 48.5, 41.1, 37.9, 34.1, 33.1, 32.1, 31.1, 25.7, 24.8; **IR** (neat, cm^{-1}): 2925 (s); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{29}\text{O}_2\text{D}$ 314.2230; found, 314.2227; $[\alpha]_{589}^{20.7}$: +81.9 (c 0.145, CHCl_3).




Data for Compound 26: For NMR Spectra of **26** see page S84. **TLC:** $R_f = 0.45$ (10% EtOAc, 10% CH_2Cl_2 in hexanes); **^1H NMR** (600 MHz, CDCl_3): δ 7.24 (d, $J = 8.7$ Hz, 1H), 6.71 (dd, $J = 8.4, 2.6$ Hz, 1H), 6.56 (d, $J = 2.9$ Hz, 1H), 4.13 – 4.06 (m, 1H), 3.76 (s, 3H), 3.30 (s, 3H), 2.86 – 2.77 (m, 3H), 2.45 (ddd, $J = 13.2, 5.9, 3.7$ Hz, 1H), 2.39 – 2.34 (m, 1H), 2.32 (dd, $J = 16.9, 5.5$ Hz, 1H), 2.18 (app t, $J = 3.7$ Hz, 1H), 2.00 (dd, $J = 11.7, 6.6$ Hz, 1H), 1.57 – 1.55 (m, 1H), 1.32 (s, 3H), 1.27 – 1.20 (m, 2H), 1.04 (s, 3H); **$^{13}\text{C}\{^1\text{H}\}$ NMR** (150 MHz, CDCl_3): δ 157.2, 138.9, 138.7, 136.8, 133.2, 126.4, 113.6, 112.0, 79.7, 56.9, 55.3, 47.9, 41.1, 39.0, 34.7, 33.9, 32.9, 31.7, 29.8, 25.8, 24.8; **IR** (neat, cm^{-1}): 2926 (s), 1710 (w); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{29}\text{O}_2\text{D}$ 314.2230; found, 314.2220; $[\alpha]_{589}^{20.9}$: -10.8 (c 0.065, CHCl_3).




^1H NMR (600 MHz, CDCl_3) of crude material containing **25** and **26**





Synthesis of Tetracycle 29: A flask containing $\text{Pd}_2(\text{dba})_3$ (95 mg, 0.104 mmol, 0.20 equiv) and *rac*-BINAP (259 mg, 0.415 mmol, 0.80 equiv) was sparged with N_2 for 5 min before the addition of **27** (for preparation see page S11) (232 mg, 0.519 mmol, 1.0 equiv) in PhMe (21 mL). 1,2,2,6,6-pentamethylpiperidine (PMP) (0.380 mL, 2.07 mmol, 4.0 equiv) was added, the N_2 inlet was removed from the septum, and vinyl tape was used to further seal the flask prior to partial immersion in a pre-heated oil bath at 110 °C until the reaction was deemed complete by TLC analysis. Upon completion, the flask was cooled to rt and concentrated *in vacuo*. The crude residue was then purified by flash chromatography using a gradient of 0–30% EtOAc in hexanes to afford **29** (23 mg, 0.078 mmol, 75%) as a clear oil.

Data for Compound 29: For NMR Spectra of **29** see page S85. **TLC:** $R_f = 0.09$ (45% EtOAc in 45% hexanes with 10% CH_2Cl_2); **^1H NMR** (600 MHz, CDCl_3): δ 7.33 (d, $J = 8.7$ Hz, 1H), 6.79 (dd, $J = 8.7, 2.8$ Hz, 1H), 6.57 (d, $J = 2.8$ Hz, 1H), 6.02 (d, $J = 9.6$ Hz, 1H), 5.78 (d, $J = 9.6$ Hz, 1H), 4.59 – 4.53 (m, 1H), 3.77 (s, 3H), 2.91 (ddd, $J = 16.5, 8.2, 2.2$ Hz, 1H), 2.81 – 2.74 (m, 2H), 2.60 – 2.57 (m, 1H), 2.41 (dd, $J = 16.5, 4.2$ Hz, 1H), 2.37 – 2.29 (m, 1H), 2.08 (dd, $J = 12.4, 6.6$ Hz, 1H), 1.58 (s, 1H), 1.51 – 1.43 (m, 4H), 1.11 (s, 3H); **$^{13}\text{C}\{^1\text{H}\}$ NMR** (150 MHz, CDCl_3): δ 157.1, 137.9, 136.7, 135.6, 134.3, 132.5, 132.1, 128.0, 113.2, 112.8, 70.7, 55.2, 49.1, 42.7, 40.6, 37.3, 33.3, 31.6, 28.1, 25.3; **IR** (neat, cm^{-1}): 3358 (b), 2953 (s); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{25}\text{O}_2$ 297.1855; found, 297.1845; $[\alpha]_{589}^{22.2}$: -217.6 (c 0.0012, CHCl_3).




Synthesis of Tetracycle 34: To a stirring solution of **23**⁷ (0.89 g, 2.9 mmol, 1.0 equiv) in 34 mL toluene at rt under N_2 atmosphere was added DIBAL-H (1.0 M in toluene, 34 mL, 34 mmol, 12 equiv). The resulting mixture was heated in an oil bath to 100 °C, refluxed overnight (approx. 20 h), and then cooled to rt. The reaction was slowly quenched by the addition of a saturated aqueous solution of Rochelle's salt, and the resulting mixture was stirred until biphasic. The organic phase was separated, the aqueous phase was acidified with 1 M aqueous HCl and extracted with EtOAc (3 x 200 mL), and the combined organic phase was dried over MgSO_4 , filtered, and concentrated *in vacuo* to afford 1.2 g of a crude amorphous yellow solid.

This crude material was then dissolved in 45 mL HFIP and cooled to 0 °C under N_2 atmosphere, and stirred for 20 min. PIDA (1.3 g, 4.2 mmol, 0.95 equiv) was added, and the resulting reaction mixture was stirred for 1 min at the same temperature (until PIDA is fully dissolved). Then, 30 mL of a saturated solution of NaHCO_3 was added. HFIP was subsequently removed from the reaction mixture under vacuum, and the mostly aqueous remains was diluted with 75 mL EtOAc. The organic phase was separated, the aqueous phase was extracted with 3 x 100 mL EtOAc, and the combined organic phase was dried over MgSO_4 , filtered, and concentrated *in vacuo*. The crude

product was purified with SiO₂ flash column chromatography to afford **34** as an amorphous tan solid (0.55 g, 1.88 mmol, 65% isolated yield over two steps).

Data for Compound 34: For NMR Spectra of **34** see page S86. ¹H NMR (600 MHz, CDCl₃) δ 7.21 (d, *J* = 10.2 Hz, 1H), 6.26 (d, *J* = 10.2 Hz, 1H), 6.14 (s, 1H), 5.45 (d, *J* = 1.7 Hz, 1H), 5.09 – 5.01 (m, 1H), 2.80 – 2.71 (m, 1H), 2.58 – 2.47 (m, 4H), 2.36 – 2.32 (m, 2H), 1.83 – 1.79 (m, 1H), 1.61 (s, 1H), 1.54 (td, *J* = 12.2, 5.9 Hz, 1H), 1.46 (s, 3H), 1.37 (dd, *J* = 12.4, 7.5 Hz, 1H), 1.00 (s, 3H); ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 185.8, 166.3, 153.5, 150.4, 137.2, 128.1, 125.5, 124.3, 123.7, 76.5, 51.6, 44.7, 43.4, 35.9, 30.1, 29.9, 29.0, 24.1, 23.8; IR (thin film, cm⁻¹): 3376, 2958, 2914, 2854, 1743, 1722, 1701, 1660; HRMS (ESI-TOF): [M+H]⁺ calcd for C₁₉H₂₂O₂ 283.1686, found 283.1698; [α]_D^{22.2}: -153.3 (*c* 0.008, CHCl₃).




Synthesis of Tetracycle 36: To a stirring solution of **35**⁷ (70 mg, 0.23 mmol, 1.0 equiv) in 3 mL toluene at rt under N₂ atmosphere was added DIBAL-H (1.0 M in hexanes, 2.3 mL, 2.3 mmol, 10 equiv). The resulting mixture was heated in an oil bath to 100 °C, refluxed overnight (approx. 16 h), and then cooled to rt. The reaction was slowly quenched by the addition of a saturated aqueous solution of Rochelle's salt, and the resulting mixture was stirred until biphasic. The organic phase was separated, the aqueous phase was acidified with 1 M aqueous HCl and extracted with EtOAc (3 x 15 mL), and the combined organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo* to afford the crude phenol as an amorphous yellow solid.

This crude material was then dissolved in 2 mL HFIP and cooled to 0 °C under N₂ atmosphere, and stirred for 20 min. PIDA (70 mg, 0.22 mmol, 1.0 equiv) was added, and the resulting reaction mixture was stirred for 1 min at the same temperature (until PIDA is fully dissolved). Then, 30 mL of a saturated solution of NaHCO₃ was added. HFIP was subsequently removed from the reaction mixture under vacuum, and the mostly aqueous remains was diluted with 20 mL EtOAc. The organic phase was separated, the aqueous phase was extracted with 3 x 15 mL EtOAc, and the combined organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude product was purified with SiO₂ flash column chromatography to afford **36** (40 mg, 0.14 mmol, 60% isolated yield over two steps) as an amorphous white solid. (Caution: Prolonged stirring of more than 30 min after PIDA addition resulted in a significantly lower yield).

Data for Compound 36: For NMR Spectra of **36** see page S87. ¹H NMR (500 MHz, CDCl₃) δ 7.16 (d, *J* = 10.1 Hz, 1H), 6.24 (d, *J* = 10.1 Hz, 1H), 6.13 (s, 1H), 5.50 (s, 1H), 5.09 – 5.01 (m, 1H), 2.78 – 2.67 (m, 2H), 2.55 – 2.50 (m, 1H), 2.46 – 2.39 (m, 1H), 2.32 (dd, *J* = 12.1, 6.5 Hz, 2H), 2.28 – 2.17 (m, 1H), 1.86 – 1.78 (m, 2H), 1.57 (app. td, *J* = 12.4, 5.5 Hz, 1H), 1.46 (s, 3H), 1.40 (dd, *J* = 12.1, 7.6 Hz, 1H), 0.88 (s, 3H); ¹³C{¹H} NMR (150 MHz, CDCl₃) δ 185.9, 166.6, 152.6, 149.5, 136.9, 128.2, 125.1, 124.7, 123.6, 76.4, 51.5, 44.7, 43.2, 36.1, 29.7, 29.0, 28.6, 24.5, 23.5; IR (thin film, cm⁻¹): 3388, 2952, 2923, 2851, 1662, 887, 731; HRMS (ESI-TOF): Calculated for C₁₉H₂₃O₂ [M+H]⁺ 283.1698, found 283.1693; [α]_D^{22.2}: +128.0 (*c* 0.042, CHCl₃).

E. Studies on the Effects of Substitution in the Friedel–Crafts Cyclization



Synthesis of Tetracycles 38 and 62: To a stirring solution of (R) -BINOL (146 mg, 0.512 mmol, 1.2 equiv) in CH₂Cl₂ (6 mL) at -78 °C was added SnCl₄ (0.426 mL, 1.0 M in CH₂Cl₂, 1.0 equiv) and the resulting solution was stirred for 30 min at -78 °C before the addition of **37**⁶ (164 mg, 0.426 mmol, 1.0 equiv) in CH₂Cl₂ (2 mL). The reaction mixture was then stirred at -78 °C for 1 h before being warmed to rt. After stirring for an additional 1 h at rt, saturated aqueous NH₄Cl (1 mL) was added. The biphasic solution was stirred for 1 h before being transferred to a separatory funnel. The phases were separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phase was washed with 5% NaOH (2 mL), dried over MgSO₄, filtered, and concentrated *in vacuo*.



The resulting crude product was dissolved in PhMe (4 mL) at rt under N₂ atmosphere. DIBAL-H (4.23 mL, 10 equiv, 1.0 M in PhMe) was added and the resulting reaction mixture was heated in an oil bath to reflux and stirred overnight. When the reaction was complete, as judged by TLC analysis, the reaction mixture was cooled to 0 °C where it was quenched slowly with ice then 2 M HCl (3 mL). The biphasic solution was separated, and the aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic phases were dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting crude product was purified by flash chromatography with a Biotage® Snap Ultra 5 g column and a gradient from 20–70% EtOAc in hexanes with an additive of 10% CH₂Cl₂ to afford the corresponding tetracycles **38** and **62** (81 mg, 0.273 mmol, 64% combined yield, 11:1 *anti:syn*) as white foams.


Data for Compound 38: For NMR Spectra of **38** see page S88. For nOe data of compound **38** see Millham et al.⁶ **TLC:** R_f = 0.32 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.10 (d, *J* = 8.5 Hz, 1H), 6.63 (app. dd, *J* = 8.5, 2.8 Hz, 1H), 6.54 (d, *J* = 2.8 Hz, 1H), 4.63 – 4.57 (m, 1H), 4.45 – 4.43 (m, 1H), 2.93 – 2.87 (m, 1H), 2.85 – 2.79 (m, 1H), 2.76 – 2.68 (m, 1H), 2.50 – 2.43 (m, 1H), 2.40 – 2.35 (m, 1H), 2.28 – 2.20 (m, 2H), 2.15 (dd, *J* = 11.9, 6.6 Hz, 1H), 1.81 – 1.74 (m, 1H), 1.73 – 1.60 (m, 4H), 1.54 (s, 1H), 1.45 (d, *J* = 5.4 Hz, 1H), 1.34 (dd, *J* = 11.9, 8.1 Hz, 1H), 0.89 (s, 3H), 0.73 (t, *J* = 7.5 Hz, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 153.1, 138.6, 138.0, 137.3, 131.3, 128.5, 128.0, 120.7, 114.8, 112.7, 71.6, 52.0, 41.5, 41.1, 37.9, 34.0, 33.5, 30.7, 30.1, 26.0, 24.8, 10.1; **IR** (neat, cm⁻¹): 3408 (s), 2954 (m), 2928 (m), 2871 (w), 1704 (w), 1658 (w), 1610 (m), **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₂₀H₂₇O₂ 299.2011; found, 299.2011; [α]_D^{22.2}: +84.1 (*c* 0.0033, CHCl₃).

Data for Compound 62: For NMR Spectra of **62** see page S89. For nOe data of compound **62** see Millham et al.⁶ **TLC:** R_f = 0.54 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.15 (d, *J* = 8.6 Hz, 1H), 6.71 (app. dd, *J* = 8.6, 2.8 Hz, 1H), 6.60 (d, *J* = 2.8 Hz, 1H), 4.15 – 4.08 (m, 1H), 3.77 (s, 3H), 3.33 (s, 3H), 2.96 – 2.90 (m, 1H), 2.78 – 2.71 (m, 2H), 2.5 – 2.43 (m, 1H), 2.41 – 2.35 (m, 1H), 2.32 – 2.21 (m, 2H), 2.16 – 2.12 (m, 1H), 1.80 – 1.74 (m, 1H), 1.71 – 1.60 (m, 4H),

1.33 – 1.29 (m, 1H), 0.88 (s, 3H), 0.72 (t, $J = 7.5$ Hz, 3H); $^{13}\text{C}\{\text{1H}\}$ NMR (150 MHz, CDCl_3): δ 157.2, 138.3, 137.8, 137.0, 131.0, 127.8, 113.3, 111.4, 80.2, 57.0, 55.2, 48.7, 41.1, 34.5, 33.7, 33.3, 30.9, 30.0, 25.8, 24.8, 10.0; IR (neat, cm^{-1}): 2934 (s), 1608 (m), 865 (w), 815 (w); HRMS (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{31}\text{O}_2$ 327.2324; found, 327.2312; $[\alpha]_{\text{D}}^{22.2}$: -93.5 (c 0.0015, CHCl_3).

^1H NMR (600 MHz, CDCl_3) of crude material containing **38** and **62**





Synthesis of Tetracycles **40 and **S32**:** To a stirring solution of (*R*)-BINOL (110 mg, 0.384 mmol, 1.2 equiv) in CH₂Cl₂ (2 mL) at $-78\text{ }^\circ\text{C}$ was added SnCl₄ (0.320 mL, 1.0 M in CH₂Cl₂, 1.0 equiv) and the resulting solution was stirred for 30 min at $-78\text{ }^\circ\text{C}$ before the addition of **39**⁶ (143 mg, 0.320 mmol, 1.0 equiv) in CH₂Cl₂ (2 mL). The reaction mixture was then stirred at $-78\text{ }^\circ\text{C}$ for 1 h before being warmed to rt. After stirring for an additional 1 h, saturated aqueous NH₄Cl (1 mL) was added. The biphasic solution was stirred for 1 h before being transferred to a separatory funnel. The phases were separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phase was washed with 5% NaOH (2 mL), dried over MgSO₄, filtered, and concentrated *in vacuo*.




The resulting crude product was dissolved in PhMe (3 mL) at rt under N₂ atmosphere. DIBAL-H (3.2 mL, 10 equiv, 1.0 M in PhMe) was added and the resulting reaction mixture was heated in an oil bath to reflux and stirred overnight. When the reaction was complete, as judged by TLC analysis, the reaction mixture was cooled to 0 °C where it was quenched slowly with ice then 2 M HCl (3 mL). The biphasic solution was separated, and the aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic phases were dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting crude product was purified by flash chromatography with a Biotage® Snap Ultra 5 g column and a gradient from 20–70% EtOAc in hexanes with an additive of 10% CH₂Cl₂ to afford the corresponding tetracycles **40** and **S32** (69 mg, 0.192 mmol, 50% combined yield, 2:1 *anti:syn*) as white foams.


Data for Compound **40:** For NMR Spectra of **40** see page S90. For nOe data of compound **40** see Millham et al.⁶ **TLC:** R_f = 0.13 (30% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.19 – 7.17 (m, 3H), 6.84 – 6.79 (m, 2H), 6.67 (d, *J* = 8.5 Hz, 1H), 6.56 – 6.50 (m, 2H), 6.08 (s, 1H), 4.58 – 4.52 (m, 1H), 3.04 – 2.93 (m, 2H), 2.88 – 2.75 (m, 3H), 2.56 – 2.45 (m, 2H), 2.31 (dd, *J* = 16.8, 4.3 Hz, 1H), 2.23 – 2.19 (m, 1H), 2.08 – 2.03 (m, 1H), 1.72 (td, *J* = 14.1, 3.3 Hz, 1H), 1.53 – 1.47 (m, 1H), 1.41 (d, *J* = 6.0 Hz, 1H), 1.32 – 1.14 (m, 1H), 1.14 (dd, *J* = 12.0, 7.7 Hz, 1H), 0.85 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 153.2, 139.2, 138.8, 138.0, 137.9, 130.8, 130.1, 128.7, 128.5, 127.6, 126.2, 114.6, 112.8, 71.6, 51.9, 47.8, 42.5, 41.2, 38.1, 32.9, 31.2, 30.8, 26.2, 24.9; **IR** (neat, cm⁻¹): 3338 (m), 2951 (s), 2850 (s), 1724 (w), 700 (m); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₂₅H₂₉O₂ 361.2168; found, 361.2158; [α]_D²²: +161.0 (*c* 0.0014, CHCl₃).

Data for Compound **S32:** For NMR Spectra of **S32** see page S91. For nOe data of compound **S32** see Millham et al.⁶ **TLC:** R_f = 0.13 (30% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.19 – 7.09 (m, 4H), 6.95 (d, *J* = 6.9 Hz, 2H), 6.62 (dd, *J* = 8.5, 2.8 Hz, 1H), 6.54 (d, *J* = 2.5 Hz, 1H), 4.99 (s, 1H), 4.52 – 4.45 (m, 1H), 3.07 (d, *J* = 13.4 Hz, 1H), 2.90 – 2.86 (m, 2H), 2.85 – 2.77 (m, 2H), 2.55 – 2.46 (m, 2H), 2.29 (dd, *J* = 16.9, 5.4 Hz, 1H), 2.04 – 1.90 (m, 3H), 1.50 (s, 2H), 1.45 (td, *J* = 12.9, 4.2 Hz, 1H), 1.32 (d, *J* = 5.7 Hz, 1H), 1.20 – 1.12 (m, 1H), 0.52 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 153.5, 139.8, 139.3, 139.0, 137.5, 130.8, 127.5, 127.3, 126.1, 115.4, 113.0, 71.2, 51.4, 49.0, 44.6, 41.2, 38.2, 33.7, 31.6, 29.4, 25.1, 25.0; **IR** (neat, cm⁻¹): 3388 (s),

2948 (m), 2921 (m), 2846 (w), 1703 (m), 701 (m); **HRMS** (ESI-TOF) (m/z): [M+H]⁺ calcd for C₂₅H₂₉O₂ 361.2168; found, 361.2158; [α]₅₈₉^{22,2}: +161.0 (c 0.0014, CHCl₃).

^1H NMR (600 MHz, CDCl_3) of crude material containing **40** and **S32**






Synthesis of Tetracycles **42 and **S33**:** To a stirring solution of (*S*)-BINOL (38 mg, 0.112 mmol, 1.1 equiv) in CH₂Cl₂ (2 mL) at $-78\text{ }^{\circ}\text{C}$ was added SnCl₄ (0.101 mL, 0.101 mmol, 1.0 equiv, 1.0 M in CH₂Cl₂) which was stirred for 30 min at $-78\text{ }^{\circ}\text{C}$ before the addition of **41** (see page S11 for preparation) (32 mg, 0.244 mmol, 1.0 equiv) in CH₂Cl₂ (2 mL). The reaction mixture was then stirred at $-78\text{ }^{\circ}\text{C}$ for 2 h before being warmed to rt. After stirring for an additional 1 h, saturated aqueous NH₄Cl (4 mL) was added. The biphasic solution was stirred for 1 h before being transferred to a separatory funnel where the phases were separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phase was washed with 3 M NaOH (3 mL), was dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting crude material containing the 4.5:1 mixture of C9 diastereomers was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g column and a gradient from 0–40% EtOAc in hexanes to afford **42** and **S33** (33 mg, 0.226 mmol, 89% combined yield) as a white foam. An additional purification with a Biotage[®] Snap Ultra 10 g column and a gradient from 0–25% EtOAc in hexanes was required to isolate each diastereomer, both of which were white foams.



Data for Compound **42:** For NMR Spectra of **42** see page S92. **TLC:** $R_f = 0.23$ (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.21 – 7.14 (m, 3H), 6.83 (dd, $J = 6.4, 3.2$ Hz, 2H), 6.78 – 6.73 (m, 1H), 6.64 – 6.59 (m, 2H), 4.57 – 4.54 (m, 1H), 3.78 (s, 3H), 3.06 – 2.97 (m, 2H), 2.88 – 2.78 (m, 3H), 2.55 – 2.49 (m, 2H), 2.32 (dd, $J = 16.7, 4.3$ Hz, 1H), 2.24 – 2.21 (m, 1H), 2.09 – 2.03 (m, 1H), 1.74 (td, $J = 14.1, 3.4$ Hz, 1H), 1.51 – 1.48 (m, 1H), 1.30 – 1.26 (m, 1H), 1.13 (dd, $J = 12.0, 7.7$ Hz, 1H), 0.85 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 157.37, 139.35, 138.88, 137.95, 137.61, 130.87, 130.21, 128.54, 127.68, 127.62, 126.24, 113.03, 111.70, 77.41, 77.20, 76.99, 71.61, 55.32, 51.93, 48.00, 42.52, 41.24, 38.18, 33.01, 31.69, 30.96, 26.29, 25.08. **IR** (neat, cm⁻¹): 3349 (b), 3026 (s), 2934 (s), 1607 (s), 736 (s), 701 (s); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for C₂₆H₃₀O₂ 374.5240; found, 374.5245; $[\alpha]_{589}^{21.9}$: -141.4 (c 0.650, CHCl₃).

Data for Compound **S33:** For and NMR Spectra of **S33** see page S93. **TLC:** $R_f = 0.23$ (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.22 – 7.12 (m, 4H), 6.99 – 6.92 (m, 2H), 6.72 (dd, $J = 8.7, 2.9$ Hz, 1H), 6.61 (d, $J = 2.9$ Hz, 1H), 4.49 – 4.45 (m, 1H), 3.79 (s, 3H), 3.09 (d, $J = 13.4$ Hz, 1H), 2.92 (dd, $J = 8.2, 5.3$ Hz, 2H), 2.86 – 2.76 (m, 2H), 2.56 – 2.51 (m, 2H), 2.30 (dd, $J = 16.9, 5.5$ Hz, 1H), 2.04 (dd, $J = 9.4, 5.1$ Hz, 1H), 2.03 – 1.96 (m, 1H), 1.96 – 1.89 (m, 1H), 1.45 (d, $J = 12.8$, 1H), 1.30 – 1.21 (m, 2H), 1.22 – 1.11 (m, 2H), 0.50 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 157.5, 140.0, 139.2, 137.7, 130.9, 130.8, 127.6, 127.2, 126.1, 113.8, 111.9, 77.4, 77.2, 77.0, 71.2, 55.3, 53.6, 51.7, 49.1, 44.7, 41.3, 38.4, 33.9, 32.0, 29.5, 25.2, 25.0; **IR** (neat, cm⁻¹): 3338 (b), 2920 (m), 1606 (s), 700 (s); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for C₂₆H₃₀O₂ 374.5240; found, 374.5243; $[\alpha]_{589}^{22.0}$: $+30.0$ (c 0.205, CHCl₃).


^1H NMR (600 MHz, CDCl_3) of crude material containing **42** and **S33**



General chromatographic mobility of C9,C13-diastereomers




*****It is important to note that all observed C₉-diastereomers of tetracycles with OMe groups at C₃ and C₁₆ have very similar R_f values and could only be separated by HPLC. As a result, isolated yield of all the following C₉,C₁₃-anti tetracycles was determined after silica plug or Biotage[®] column purification with no indication of C₉,C₁₃-syn isomers unless otherwise noted.**




Synthesis of Tetracycles 44 and S34: To a stirring solution of (*S*)-BINOL (23 mg, 0.0788 mmol, 1.1 equiv) in CH₂Cl₂ (2 mL) at -78 °C was added SnCl₄ (0.072 mL, 0.0716 mmol, 1.0 equiv, 1.0 M in CH₂Cl₂) which was stirred for 30 min at that temperature before the addition of **43** (see page S12 for preparation) (33 mg, 0.0716 mmol, 1.0 equiv) in CH₂Cl₂ (2 mL), and the solution was kept at that temperature for 2 h before being warmed to rt. After stirring for an additional 1 h, the reaction was quenched with saturated aqueous NH₄Cl (4 mL). The biphasic solution was stirred for 1 h before being transferred to a separatory funnel where the phases were separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phase was washed with 3 M NaOH (3 mL), was dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting crude product containing the 10:1 mixture of C₉ diastereomers was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g column and a gradient from 0–20% EtOAc in hexanes to afford **44** and **S34** as a mixture of diastereomers (14 mg, 0.0360 mmol, 46% combined yield) as a white foam. The mixture was purified by HPLC with a gradient from 0–15% EtOAc in hexanes to afford the isolated diastereomers **44** and **S34** as white foams.



Data for Compound 44: For NMR Spectra of **44** see page S97. **TLC:** $R_f = 0.49$ (20% EtOAc in hexanes); $^1\text{H NMR}$ (600 MHz, CDCl_3): δ 7.16 – 7.14 (m, 3H), 6.78 – 6.76 (m, 2H), 6.68 (d, $J = 8.5$ Hz, 1H), 6.62 (d, $J = 2.4$ Hz, 1H), 6.59 (dd, $J = 8.9, 2.8$ Hz, 1H), 4.14 – 4.10 (m, 1H), 3.78 (s, 3H), 3.34 (s, 3H), 3.02 – 2.98 (m, 2H), 2.86 (d, $J = 13.4$ Hz, 1H), 2.82 – 2.78 (m, 2H), 2.53 – 2.45 (m, 2H), 2.34 (dd, $J = 17.4, 4.5$ Hz, 1H), 2.20 (d, $J = 13.8$ Hz, 1H), 2.07 (dd, $J = 6.6, 5.5$ Hz, 1H), 1.71 (td, $J = 14.5, 3.5$ Hz, 1H), 1.55 – 1.52 (m, 1H), 1.40 – 1.36 (m, 1H), 1.18 (app. t, $J = 10.0$ Hz, 1H), 0.86 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 157.2, 139.0, 138.1, 137.6, 137.4, 130.7, 129.8, 128.4, 127.4, 125.9, 112.8, 111.3, 80.0, 56.8, 55.1, 48.2, 47.2, 42.3, 40.9, 34.5, 32.6, 31.2, 30.3, 25.8, 24.7; **IR** (neat, cm^{-1}): 2954 (m), 1733 (s), 1607 (s), **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{33}\text{O}_2$ 389.2481; found, 389.2472; $[\alpha]_{589}^{20.8}$: -192.7 (c 0.845, CHCl_3).




Data for Compound S34: For NMR Spectra of **S34** see page S98. **TLC:** $R_f = 0.49$ (20% EtOAc in hexanes); $^1\text{H NMR}$ (600 MHz, CDCl_3): δ 7.20 – 7.13 (m, 4H), 6.97 – 6.94 (m, 2H), 6.71 (dd, $J = 8.7, 2.9$ Hz, 1H), 6.60 (d, $J = 2.8$ Hz, 1H), 4.03 – 4.00 (m, 1H), 3.79 (s, 3H), 3.28 (s, 3H), 3.09 (d, $J = 13.4$ Hz, 1H), 2.92 – 2.88 (m, 2H), 2.81 – 2.76 (m, 2H), 2.55 – 2.48 (m, 2H), 2.32 (dd, $J = 17.0, 5.7$ Hz, 1H), 2.05 – 2.01 (m, 1H), 1.98 (dd, $J = 12.7, 3.5$ Hz, 1H), 1.91 (dd, $J = 11.8, 6.4$ Hz, 1H), 1.46 – 1.42 (m, 1H), 1.17 – 1.12 (m, 2H), 0.50 (s, 3H).; $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 157.6, 139.8, 139.3, 137.8, 130.9, 130.9, 127.7, 127.2, 126.2, 113.8, 111.9, 79.8, 77.5, 77.3, 77.1, 57.1, 55.4, 49.1, 48.2, 44.8, 41.1, 35.1, 33.8, 31.9, 29.6, 25.3, 25.0. **IR** (neat, cm^{-1}): 3082 (s), 2920 (w), 1608 (s), 757 (w); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{33}\text{O}_2$ 389.2481; found, 389.2468; $[\alpha]_{589}^{20.8}$: $+87.7$ (c 3.125, CHCl_3).



^1H NMR (600 MHz, CDCl_3) of crude material containing **44** and **S34**




S40



Synthesis of Hydrindane 45: To a stirring solution of hydrindane **41** (for preparation see page S11) (58 mg, 0.1298 mmol, 1.0 equiv) at 0 °C in CH₂Cl₂ (2 mL) was slowly added TFA (13 μL, 0.168 mmol, 1.1 equiv). The reaction mixture was stirred at 0 °C for 1 h (reaction progress was monitored by TLC, 30% EtOAc in hexanes). Once the reaction was complete by TLC the mixture was quenched with DI water (3 mL), followed by dilution with CH₂Cl₂ (5 mL), the biphasic solution was separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phases were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage® Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford the protodesilylated hydrindane as a clear oil which was immediately used in the next reaction.


To a stirring solution of the protodesilylated hydrindane in THF (2 mL) at 0 °C was added NaH in a 60% oil suspension (19 mg, 0.348 mmol, 3 equiv), and the solution was stirred for 10 min before the addition of MeI (57 μL, 0.696 mmol, 6 equiv). The solution was warmed to rt and stirred overnight (~ 14 h). Upon completion, the reaction was cooled to 0 °C and quenched with saturated aqueous NaHCO₃ (3 mL), the phases were separated, and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage® Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford hydrindane **45** as a clear oil (35.1 mg, 0.0903 mmol, 70% over two steps).

Data for Compound 45: For NMR Spectra of **45** see page S96. **TLC:** R_f = 0.40 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.17 (app. t, *J* = 7.5 Hz, 2H), 7.11 – 7.04 (m, 4H), 6.65 – 6.59 (m, 2H), 6.54 (d, *J* = 2.5 Hz, 1H), 5.31 (d, *J* = 6.3 Hz, 1H), 3.89 (app. p, *J* = 7.5 Hz, 1H), 3.68 (s, 3H), 3.43 – 3.33 (m, 2H), 3.20 (s, 3H), 2.60 (dd, *J* = 18.1, 8.0 Hz, 1H), 2.44 (ddd, *J* = 15.0, 10.1, 5.7 Hz, 1H), 2.34 (ddd, *J* = 13.4, 9.6, 6.8 Hz, 1H), 2.23 – 2.08 (m, 3H), 2.06 – 1.97 (m, 3H), 1.34 (dd, *J* = 11.9, 9.1 Hz, 1H), 0.85 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 159.5, 143.8, 143.3, 140.7, 135.7, 129.2, 128.7, 128.3, 128.3, 127.3, 125.9, 122.1, 120.9, 114.4, 111.0, 80.2, 56.9, 55.1, 47.7, 39.7, 39.4, 37.6, 35.4, 34.6, 31.5, 22.1; **IR** (neat, cm⁻¹): 2922 (m), 1601 (m), 697 (m); **HRMS** (ESI-TOF) (*m/z*): [M-H]⁺ calcd for C₂₇H₃₁O₂ 387.2324; found, 387.2308; [α]_D^{20.9}: –12.7 (*c* 1.56, CHCl₃).





Synthesis of Tetracycle 44: To a stirring solution of (*S*)-BINOL (77 mg, 0.268 mmol, 1.1 equiv) in CH₂Cl₂ (2 mL) at $-78\text{ }^{\circ}\text{C}$ was added SnCl₄ (0.031 mL, 0.250 mmol, 1.0 equiv, 1.0 M in CH₂Cl₂) which was stirred for 30 min at that temperature before the addition of **45** (93 mg, 0.244 mmol, 1.0 equiv) in CH₂Cl₂ (2 mL), and the solution was kept at $-78\text{ }^{\circ}\text{C}$ for 2 h before being warmed to rt. After stirring for an additional 1 h, the reaction was quenched with saturated aqueous NH₄Cl (4 mL). The biphasic solution was stirred for 1 h before being transferred to a separatory funnel where the phases were separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phase was washed with 3 M NaOH (3 mL), was dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting crude product was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g column and a gradient from 0-15% EtOAc in hexanes to afford **44** isolated as a single diastereomer (see note on page S36) (88 mg, 0.226 mmol, 91%) as a white foam.

Data for Compound 44: For NMR Spectra of **44** see page S97. **TLC:** R_f = 0.49 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.16 – 7.14 (m, 3H), 6.78 – 6.76 (m, 2H), 6.68 (d, *J* = 8.5 Hz, 1H), 6.62 (d, *J* = 2.4 Hz, 1H), 6.59 (dd, *J* = 8.9, 2.8 Hz, 1H), 4.14 – 4.10 (m, 1H), 3.78 (s, 3H), 3.34 (s, 3H), 3.02 – 2.98 (m, 2H), 2.86 (d, *J* = 13.4 Hz, 1H), 2.82 – 2.78 (m, 2H), 2.53 – 2.45 (m, 2H), 2.34 (dd, *J* = 17.4, 4.5 Hz, 1H), 2.20 (d, *J* = 13.8 Hz, 1H), 2.07 (dd, *J* = 6.6, 5.5 Hz, 1H), 1.71 (td, *J* = 14.5, 3.5 Hz, 1H), 1.55 – 1.52 (m, 1H), 1.40 – 1.36 (m, 1H), 1.18 (app. t, *J* = 10.0 Hz, 1H), 0.86 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 157.2, 139.0, 138.1, 137.6, 137.4, 130.7, 129.8, 128.4, 127.4, 125.9, 112.8, 111.3, 80.0, 56.8, 55.1, 48.2, 47.2, 42.3, 40.9, 34.5, 32.6, 31.2, 30.3, 25.8, 24.7; **IR** (neat, cm⁻¹): 2954 (m), 1733 (s), 1607 (s), **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₂₇H₃₃O₂ 389.2481; found, 389.2472; [α]_D^{20.8}₅₈₉: -192.7 (*c* 0.845, CHCl₃).




^1H NMR (600 MHz, CDCl_3) of **44** after Biotage[®] column purification



S43


F. Synthesis of C9,C13-Anti-Substituted Tetracycle



Synthesis of Hydrindane S36: To a stirring solution of hydrindane **S35**⁷ (43 mg, 0.116 mmol, 1.0 equiv) at 0 °C in CH₂Cl₂ (2 mL) was slowly added TFA (10 μL, 0.128 mmol, 1.1 equiv). The reaction mixture was stirred at 0 °C for 2 min (reaction progress was monitored by TLC, 30% EtOAc in hexanes). Once the reaction was complete by TLC the mixture was quenched with DI water (3 mL), followed by dilution with CH₂Cl₂ (5 mL), the biphasic solution was separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phases were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford the protodesilylated hydrindane as a clear oil which was immediately used in the next reaction.


To a stirring solution of the protodesilylated hydrindane in THF (2 mL) at 0 °C was added NaH in a 60% oil suspension (14 mg, 0.348 mmol, 3 equiv), and the solution was stirred for 10 min before the addition of MeI (43 μL, 0.696 mmol, 6 equiv). The solution was warmed to rt and stirred overnight (~ 14 h). Upon completion, the reaction was cooled to 0 °C and quenched with a saturated aqueous solution of NaHCO₃ (3 mL), the phases were separated, and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g cartridge and a gradient from 0-15% EtOAc in hexanes to afford hydrindane **S36** as a clear oil (20 mg, 0.064 mmol, 55% over two steps).


Data for Compound S36: For NMR Spectra of **S36** see page S99. **TLC:** R_f = 0.29 (5% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.19 (app. t, *J* = 7.8 Hz, 1H), 6.78 (d, *J* = 7.7 Hz, 1H), 6.75 – 6.69 (m, 2H), 5.39 (d, *J* = 6.1 Hz, 1H), 4.01 – 3.96 (m, *J* = 7.4 Hz, 1H), 3.79 (s, 3H), 3.30 (s, 3H), 2.66 (dd, *J* = 17.3, 7.9 Hz, 1H), 2.62 – 2.53 (m, 2H), 2.39 – 2.28 (m, 2H), 2.15 – 2.01 (m, 4H), 1.82 (s, 3H), 1.41 (app. t, *J* = 10.3 Hz, 1H), 0.88 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 159.7, 144.0, 142.4, 132.7, 129.3, 127.7, 121.1, 119.8, 114.6, 111.1, 80.4, 57.0, 55.3, 47.8, 40.0, 37.7, 35.6, 34.6, 31.8, 22.3, 19.4; **IR** (neat, cm⁻¹): 3376 (m, br), 2935 (s), 2834 (w), 1734 (m), 756 (m), 698 (m); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₂₁H₂₉O₂ 313.2168; found, 313.2154; [α]_D^{22.5}: -3.8 (*c* 0.00135, CHCl₃).



Synthesis of Tetracycle 46: To a stirring solution of (*S*)-BINOL (28.3 mg, 0.0987 mmol, 1.2 equiv) in CH₂Cl₂ (1.0 mL) at $-78\text{ }^{\circ}\text{C}$ was added SnCl₄ (0.82 mL, 0.0823 mmol, 1.0 equiv, 1.0 M in CH₂Cl₂) which was stirred for 30 min at that temperature before the addition of **S36** (25.7 mg, 0.0823 mmol, 1.0 equiv) in CH₂Cl₂ (0.5 mL), and the solution was kept at $-78\text{ }^{\circ}\text{C}$ for 2 h before being warmed to rt. After stirring for an additional 1 h, the reaction was quenched with saturated aqueous NH₄Cl (2 mL). The biphasic solution was stirred for 1 h before being transferred to a separatory funnel where the phases were separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phase was washed with 2 M NaOH (1 mL), was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude product was filtered through silica to afford **46** (25.3 mg, 0.0810 mmol, 98%) as a clear oil.

Data for Compound 46: For NMR Spectra of **46** see page S100. **TLC:** R_f = 0.30 (10% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.22 (d, J = 8.7 Hz, 1H), 6.76 (d, J = 8.4 Hz, 1H), 6.59 (d, J = 2.3 Hz, 1H), 4.16 – 4.10 (m, 1H), 3.78 (s, 3H), 3.34 (s, 3H), 2.91 – 2.85 (m, 1H), 2.81 – 2.68 (m, 2H), 2.46 – 2.41 (m, 1H), 2.39 – 2.30 (m, 2H), 2.16 (dd, J = 11.7, 6.7 Hz, 1H), 2.10 – 2.07 (m, 1H), 1.88 – 1.81 (m, 1H), 1.74 – 1.69 (m, 2H), 1.14 – 1.13 (m, 4H), 0.90 (s, 3H); **¹³C{¹H}** **NMR** (150 MHz, CDCl₃): δ 157.1, 140.2, 137.3, 136.1, 131.7, 127.2, 113.1, 112.5, 80.3, 56.9, 55.3, 48.7, 41.2, 38.1, 34.4, 33.3, 32.3, 31.3, 29.8, 25.8, 25.0; **IR** (neat, cm⁻¹): 2931 (s), 1608 (m); **HRMS** (ESI-TOF) (m/z): [[M+H]⁺ calcd for C₂₁H₂₉O₂ 313.2168; found, 313.2159; [α]_D²⁵: -154.1 (c 0.00007, CHCl₃).






Synthesis of Hydrindane S37: To a stirring solution of hydrindane **S21** (for preparation see page S12) (43 mg, 0.0876 mmol, 1.0 equiv) at 0 °C in CH₂Cl₂ (2 mL) was slowly added TFA (7.4 μL, 0.0964 mmol, 1.1 equiv). The reaction mixture was stirred at 0 °C for 30 mins (reaction progress was monitored by TLC, 30% EtOAc in hexanes). Once reaction was complete by TLC the mixture was quenched with DI water (3 mL), followed by dilution with CH₂Cl₂ (5 mL), the biphasic solution was separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phases were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage® Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford protodesilylated hydrindane as a clear oil which was immediately used in the next reaction.


To a stirring solution of the protodesilylated hydrindane in THF (2 mL) at 0 °C was added NaH in a 60% oil suspension (11 mg, 0.263 mmol, 3 equiv), and the solution was stirred for 10 min before the addition of MeI (33 μL, 0.526 mmol, 6 equiv). The solution was warmed to rt and stirred overnight (~ 14 h). Upon completion, the reaction was cooled to 0 °C and quenched with a saturated aqueous solution of NaHCO₃ (3 mL), the phases were separated, and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage® Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford hydrindane **S37** as a clear oil (21 mg, 0.0485 mmol, 55% over two steps).


Data for Compound S37: For NMR Spectra of **S37** see page S102. **TLC:** $R_f = 0.37$ (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.37 – 7.29 (m, 5H), 7.20 – 7.17 (m, 1H), 6.81 – 6.75 (m, 2H), 6.73 (d, $J = 2.3$ Hz, 1H), 5.49 (dd, $J = 6.7, 2.5$ Hz, 1H), 4.54 (d, $J = 1.7$ Hz, 2H), 4.02 – 3.96 (m, 1H), 3.81 (d, $J = 1.0$ Hz, 3H), 3.56 – 3.47 (m, 2H), 3.35 – 3.29 (m, 3H), 2.72 (dd, $J = 17.9, 7.9$ Hz, 1H), 2.63 – 2.59 (m, 1H), 2.54 – 2.46 (m, 3H), 2.41 – 2.31 (m, 2H), 2.15 – 2.06 (m, 3H), 1.41 (dd, $J = 11.8, 9.1$ Hz, 1H), 0.89 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 143.7, 143.0, 133.6, 129.2, 128.4, 127.6, 127.5, 127.0, 121.0, 120.9, 114.5, 111.0, 80.2, 43.0, 70.5, 56.9, 55.2, 47.6, 37.4, 35.5, 34.7, 32.9, 31.5, 22.0; **IR** (neat, cm⁻¹): 3029 (s), 2923 (m), 2858 (m), 776 (m), 697 (s); **HRMS** (ESI-TOF) (m/z): $[M+H]^+$ calcd for C₂₉H₃₇O₃ 433.2664; found, 433.2702; $[\alpha]_{589}^{22.1}$: -26.2 (c 0.15, CHCl₃).



Synthesis of Tetracycline 47: To a stirring solution of (*S*)-BINOL (22 mg, 0.074 mmol, 1.1 equiv) in CH₂Cl₂ (1 mL) at $-78\text{ }^{\circ}\text{C}$ was added SnCl₄ (0.067 mL, 0.067 mmol, 1.0 equiv, 1.0 M in CH₂Cl₂) which was stirred for 30 min at that temperature before the addition of **S37** (29 mg, 0.067 mmol, 1.0 equiv) in CH₂Cl₂ (1 mL), and the solution was warmed to $-40\text{ }^{\circ}\text{C}$ and kept at that temperature for 2 h before being warmed to rt. After stirring for an additional 1 h, the reaction was quenched with saturated aqueous NH₄Cl (2 mL). The biphasic solution was stirred for 1 h before being transferred to a separatory funnel where the phases were separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 5 mL). The combined organic phase was washed with 3 M NaOH (3 mL), was dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting crude product was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g column and a gradient from 0-15% EtOAc in hexanes to afford **47** (13 mg, 0.018 mmol, 45%) as a white foam.

Data for Compound 47: For NMR Spectra of **47** see page S103. **TLC:** $R_f = 0.37$ (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.32 – 7.30 (m, 2H), 7.27 – 7.25 (m, 3H), 7.16 (d, $J = 8.6$ Hz, 1H), 6.70 (dd, $J = 8.7, 2.7$ Hz, 1H), 6.60 (d, $J = 2.8$ Hz, 1H), 4.40 – 4.33 (m, 2H), 4.12 (ddd, $J = 14.5, 10.4, 6.5$ Hz, 1H), 3.77 (s, 3H), 3.40 – 3.31 (m, 5H), 2.95 – 2.90 (m, 1H), 2.77 – 2.71 (m, 2H), 2.41 – 2.37 (m, 2H), 2.34 – 2.25 (m, 2H), 2.14 (dd, $J = 11.7, 6.6$ Hz, 1H), 2.01 – 1.97 (m, 2H), 1.86 – 1.80 (m, 1H), 1.72 – 1.66 (m, 2H), 1.34 – 1.28 (m, 1H), 0.87 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 157.2, 138.6, 137.7, 137.7, 137.6, 130.1, 128.3, 127.5, 127.4, 127.3, 113.1, 111.6, 80.0, 72.8, 68.3, 56.8, 55.1, 48.5, 41.0, 40.4, 40.1, 34.4, 33.2, 31.6, 30.7, 25.7, 24.8; **IR** (neat, cm⁻¹): 2921 (s), 2850 (m); **HRMS** (ESI-TOF) (m/z): [M+Na]⁺ calcd for C₂₉H₃₆O₃Na 455.2664; found, 455.2562; $[\alpha]_{589}^{21.6}$: -138.6 (c 0.04, CHCl₃).






Synthesis of Hydrindane S38: To a stirring solution of hydrindane **S22** (for preparation see page S13) (43 mg, 0.104 mmol, 1.0 equiv) at 0 °C in CH₂Cl₂ (2 mL) was slowly added TFA (9 μL, 0.094 mmol, 1.1 equiv). The reaction mixture was stirred at 0 °C for 5 mins (reaction progress was monitored by TLC, 30% EtOAc in hexanes). Once reaction was complete by TLC the mixture was quenched with DI water (3 mL), followed by dilution with CH₂Cl₂ (5 mL), the biphasic solution was separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phases were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford the protodesilylated hydrindane as a clear oil which was immediately used in the next reaction.



To a stirring solution of the protodesilylated hydrindane in THF (2 mL) at 0 °C was added NaH in a 60% oil suspension (12.5 mg, 0.312 mmol, 3 equiv), and the solution was stirred for 10 min before the addition of MeI (40 μL, 0.624 mmol, 6 equiv). The solution was warmed to rt and stirred overnight (~ 14 h). Upon completion, the reaction was cooled to 0 °C and quenched with a saturated aqueous solution of NaHCO₃ (3 mL), the phases were separated, and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford hydrindane **S38** as a clear oil (20.2 mg, 0.0570 mmol, 55% over two steps).

Data for Compound S38: For NMR Spectra of **S38** see page S105. **TLC:** R_f = 0.46 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.19 (app. t, *J* = 7.9 Hz, 1H), 6.78 (d, *J* = 7.3 Hz, 1H), 6.74 (d, *J* = 8.4 Hz, 1H), 6.72 (s, 1H), 5.40 (d, *J* = 5.5 Hz, 1H), 4.00 – 3.98 (m, 1H), 3.80 (s, 3H), 3.31 (s, 3H), 2.73 (dd, *J* = 18.0, 7.7 Hz, 1H), 2.66 – 2.57 (m, 1H), 2.55 – 2.49 (m, 1H), 2.38 – 2.29 (m, 2H), 2.21 – 2.15 (m, 1H), 2.14 – 2.05 (m, 5H), 1.48 – 1.27 (m, 5H), 0.91 (t, *J* = 6.6 Hz, 3H), 0.89 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 159.7, 144.1, 142.7, 137.3, 129.4, 127.6, 121.1, 119.1, 114.6, 111.1, 80.4, 57.1, 55.3, 47.8, 39.8, 37.6, 35.7, 34.8, 32.6, 31.9, 31.6, 22.7, 22.2, 14.2; **IR** (neat, cm⁻¹): 2926 (s), 2871 (m), 776 (w), 696 (m); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₂₄H₃₅O₂ 355.2637; found, 355.2631; [α]_D^{22.5}: -23.4 (*c* 0.0020, CHCl₃).



Synthesis of Tetracycle 48: To a stirring solution of (*S*)-BINOL (18 mg, 0.0620 mmol, 1.1 equiv) in CH₂Cl₂ (1.0 mL) at $-78\text{ }^\circ\text{C}$ was added SnCl₄ (56 μL , 0.0564 mmol, 1.0 equiv, 1.0 M in CH₂Cl₂) which was stirred for 30 min at that temperature before the addition of **S38** (20 mg, 0.0564 mmol, 1.0 equiv) in CH₂Cl₂ (0.5 mL), and the solution was kept at $-78\text{ }^\circ\text{C}$ for 2 h before being warmed to rt. After stirring for an additional 1 h, the reaction was quenched with saturated aqueous NH₄Cl (2 mL). The biphasic solution was stirred for 1 h before being transferred to a separatory funnel where the phases were separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phase was washed with 2 M NaOH (1 mL), was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude product was filtered through silica to afford **48** (13.8 mg, 0.0389 mmol, 69%) as a clear oil.


Data for Compound 48: For NMR Spectra of **48** see page S106. **TLC:** $R_f = 0.37$ (10% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.16 (d, $J = 8.8$ Hz, 1H), 6.71 (dd, $J = 8.8, 2.6$ Hz, 1H), 6.60 (d, $J = 2.6$ Hz, 1H), 4.15 – 4.09 (m, 1H), 3.77 (s, 3H), 3.33 (s, 3H), 2.93 (dt, $J = 16.1, 5.7$ Hz, 1H), 2.79 – 2.70 (m, 2H), 2.50 – 2.42 (m, 1H), 2.41 – 2.34 (m, 1H), 2.29 (dd, $J = 17.2, 4.4$ Hz, 1H), 2.24 (dt, $J = 11.4, 6.6$ Hz, 1H), 2.14 (dd, $J = 11.4, 6.6$ Hz, 1H), 1.80 (td, $J = 13.4, 4.0$ Hz, 1H), 1.71 – 1.53 (m, 4H), 1.31 (dd, $J = 11.4, 8.8$ Hz, 1H), 1.20 – 1.10 (m, 3H), 1.08 – 1.00 (m, 1H), 0.87 (s, 3H), 0.80 (t, $J = 7.0$ Hz, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 157.1, 138.9, 137.7, 136.9, 131.0, 127.7, 113.2, 111.5, 80.3, 57.0, 55.2, 48.7, 41.7, 41.1, 41.0, 34.5, 33.5, 31.0, 30.9, 29.8, 27.8, 25.8, 24.8, 23.6, 41.2; **IR** (neat, cm⁻¹): 2931 (s), 1739 (w), 865 (w), 816 (w), 757 (m), **HRMS** (ESI-TOF) (m/z): $[M+H]^+$ calcd for C₂₄H₃₅O₂ 355.2637; found, 355.2634 ; $[\alpha]_{589}^{22.6}$: -154.1 (c 0.0007, CHCl₃).



Synthesis of Hydrindane S39: To a stirring solution of hydrindane **S24** (for preparation see page S14) (80 mg, 0.173 mmol, 1.0 equiv) at 0 °C in CH₂Cl₂ (2 mL) was slowly added TFA (15 μL, 0.190 mmol, 1.1 equiv). The reaction mixture was stirred at 0 °C for 5 mins (reaction progress was monitored by TLC, 30% EtOAc in hexanes). Once reaction was complete by TLC the mixture was quenched with DI water (3 mL), followed by dilution with CH₂Cl₂ (5 mL), the biphasic solution was separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phases were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford the protodesilylated hydrindane as a clear oil which was immediately used in the next reaction.

To a stirring solution of the protodesilylated hydrindane in THF (2 mL) at 0 °C was added NaH in a 60% oil suspension (21 mg, 0.519 mmol, 3 equiv), and the solution was stirred for 10 min before the addition of MeI (65 μL, 1.038 mmol, 6 equiv). The solution was warmed to rt and stirred overnight (~ 14 h). Upon completion, the reaction was cooled to 0 °C and quenched with a saturated aqueous solution of NaHCO₃ (3 mL), the phases were separated, and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford hydrindane **S39** as a clear oil (38.5 mg, 0.095 mmol, 55% over two steps).

Data for Compound S39: For NMR Spectra of **S39** see page S108. **TLC:** R_f = 0.43 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.14 (d, *J* = 8.4, 2H), 7.08 (app. t, *J* = 7.7, 1H), 6.9 (d, *J* = 8.3 Hz, 2H), 6.66 (dd, *J* = 8.8, 2.2 Hz, 1H), 6.49 (d, 7.5 Hz, 1H), 6.34 (s, 1H), 5.61 (app t, *J* = 4.6 Hz, 1H), 4.07 – 4.02 (m, 1H), 3.82 (s, 3H), 3.71 (s, 3H), 3.34 (s, 3H), 2.82 (dd, *J* = 18.0, 7.8 Hz, 1H), 2.36 – 2.22 (m, 6H), 2.18 (dd, *J* = 18.4, 7.4 Hz, 1H), 2.12 (dd, 12.0, 6.1 Hz, 1H), 1.46 (app. t, *J* = 10.5 Hz, 1H), 0.99 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 159.3, 158.4, 143.8, 143.4, 139.5, 134.1, 129.1, 127.0, 126.9, 122.8, 120.8, 113.9, 113.3, 111.1, 80.2, 56.9, 55.2, 55.0, 47.5, 39.7, 37.8, 34.9, 34.7, 32.4, 22.2; **IR** (neat, cm⁻¹): 2923 (m), 836 (s), 697 (s); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₂₇H₃₃O₃ 405.2430; found, 405.2427; [α]_D^{21.7}: +24.8 (*c* 0.145, CHCl₃).




Synthesis of Tetracycle 49: To a stirring solution of (*S*)-BINOL (10 mg, 0.034 mmol, 1.1 equiv) in CH₂Cl₂ (1 mL) at –78 °C was added SnCl₄ (0.031 mL, 0.031 mmol, 1.0 equiv, 1.0 M in CH₂Cl₂) which was stirred for 30 min at that temperature before the addition of **S39** (12.5 mg, 0.031 mmol, 1.0 equiv) in CH₂Cl₂ (1 mL), and the solution was kept at –78 °C for 2 h before being warmed to rt. After stirring for an additional 1 h, the reaction was quenched with saturated aqueous NH₄Cl (2 mL). The biphasic solution was stirred for 1 h before being transferred to a separatory funnel where the phases were separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 5 mL). The combined organic phase was washed with 3 M NaOH (3 mL), was dried over MgSO₄, filtered, and

concentrated *in vacuo*. The resulting crude product was purified by flash chromatography with a Biotage® Snap Ultra 5 g column and a gradient from 0-15% EtOAc in hexanes to afford **49** (7.2 mg, 0.018 mmol, 58%) as a white foam.

Data for Compound 49: For NMR Spectra of **49** see page S109. **TLC:** $R_f = 0.40$ (20% EtOAc in hexanes); **^1H NMR** (600 MHz, CDCl_3): δ 7.54 (d, $J = 8.5$ Hz, 1H), 6.94 (d, 8.5 Hz, 2H), 6.84 (dd, $J = 8.7, 2.1$ Hz, 1H), 6.71 (d, $J = 8.5$ Hz, 2H), 6.64 (s, 1H), 4.20 – 4.17 (m, 1H), 3.80 (s, 3H), 3.74 (s, 3H), 3.39 (s, 3H), 2.73 (dd, $J = 17.4, 8.7$ Hz, 1H), 2.51 (dd, $J = 16.2, 7.1$ Hz, 1H), 2.44 – 2.41 (m, 2H), 2.36 (dd, $J = 17.2, 4.5$ Hz, 1H), 2.25 – 2.10 (m, 3H), 2.07 (d, $J = 12.9$ Hz, 1H), 1.54 – 1.48 (m, 2H), 1.40 (app. t, $J = 10.1$ Hz, 1H), 0.96 (s, 3H); **$^{13}\text{C}\{^1\text{H}\}$ NMR** (150 MHz, CDCl_3): δ 157.8, 157.4, 140.6, 139.8, 139.4, 137.7, 128.6, 113.6, 112.9, 110.7, 80.1, 56.0, 55.2, 55.1, 48.5, 47.1, 41.3, 34.6, 47.1, 41.3, 34.6, 31.3, 28.2, 26.8, 25.6; **IR** (neat, cm^{-1}): 2926 (m), 1733 (s), 1717 (m), 1698 (m), 829 (s); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{33}\text{O}_3$ 405.2430; found, 405.2418; $[\alpha]_{\text{D}}^{21.8}$: +103.7 (c 0.15, CHCl_3).


***Stereochemistry at C9 of compound **49** was assigned by analogy. The chemical shift of the C13 angular methyl on compound **49** (0.96 ppm) was nearly identical to the C13 angular methyl (0.97 ppm) of the *anti*-isomer of a similar substrate with aryl functionality at C9 reported by Millham *et al.*⁶



Synthesis of S40: To a stirring solution of hydrindane **S25** (for preparation see page S15) (38 mg, 0.085 mmol, 1.0 equiv) at 0 °C in CH_2Cl_2 (2 mL) was slowly added TFA (7 μL , 0.094 mmol, 1.1 equiv). The reaction mixture was stirred at 0 °C for 5 mins (reaction progress was monitored by TLC, 30% EtOAc in hexanes). Once reaction was complete by TLC the mixture was quenched with DI water (3 mL), followed by dilution with CH_2Cl_2 (5 mL), the biphasic solution was separated, and the aqueous phase was extracted with CH_2Cl_2 (3 x 10 mL). The combined organic phases were dried over Na_2SO_4 , filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage® Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford protodesilylated hydrindane as a clear oil which was immediately used in the next reaction.



To a stirring solution of the protodesilylated hydrindane in THF (2 mL) at 0 °C was added NaH in a 60% oil suspension (10 mg, 0.255 mmol, 3 equiv), and the solution was stirred for 10 min before the addition of MeI (32 μL , 0.510 mmol, 6 equiv). The solution was warmed to rt and stirred overnight (~ 14 h). Upon completion, the reaction was cooled to 0 °C and quenched with a saturated aqueous solution of NaHCO_3 (3 mL), the phases were separated, and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic phase was dried over Na_2SO_4 , filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage® Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford hydrindane **S40** as a clear oil (18 mg, 0.0463 mmol, 55% over two steps).

Data for Compound S40: For NMR Spectra of **S40** see page S111. **TLC:** $R_f = 0.43$ (20% EtOAc in hexanes); **^1H NMR** (600 MHz, CDCl_3): δ 7.28 – 7.25 (m, 2H), 7.20 (app. t, $J = 7.7$ Hz, 2H), 7.09 (d, $J = 7.4$ Hz, 2H), 6.80 (d, $J = 7.4$ Hz, 1H), 6.81 – 6.74 (m, 2H), 5.50 (d, $J = 5.9$ Hz, 1H), 3.90 – 3.85 (m, 1H), 3.80 (s, 3H), 3.27 (s, 3H), 2.65 – 2.56 (m, 4H), 2.45 – 2.36 (m, 3H), 2.30 (dd, $J = 6.6, 6.0$ Hz, 1H), 2.14 (dd, $J = 17.8, 6.3$ Hz, 2H), 1.91 (s, 1H), 1.89 (s, 3H), 1.19 (dd, $J = 10.7, 3.9$ Hz, 1H); **$^{13}\text{C}\{^1\text{H}\}$ NMR** (150 MHz, CDCl_3): δ 157.8, 157.4, 140.6, 139.8, 139.4, 137.7, 128.6, 113.6, 112.1, 110.7, 80.1, 57.0, 55.2, 55.1, 48.5, 47.1, 41.3, 34.6, 47.1, 41.3, 34.6, 31.3, 28.2, 26.8, 25.6; **IR** (neat, cm^{-1}): 2926 (m), 1733 (s), 1717 (m), 1698 (m), 829 (s); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{33}\text{O}_3$ 389.2481; found, 389.2465; $[\alpha]_{589}^{21.8}$: +103.7 (c 0.15, CHCl_3).



Synthesis of 50: To a stirring solution of (*S*)-BINOL (37 mg, 0.127 mmol, 1.1 equiv) in CH_2Cl_2 (1 mL) at -78°C was added SnCl_4 (0.116 mL, 0.116 mmol, 1.0 equiv, 1.0 M in CH_2Cl_2) which was stirred for 30 min at that temperature before the addition of **S40** (45 mg, 0.116 mmol, 1.0 equiv) in CH_2Cl_2 (1 mL), and the solution was kept at -78°C for 2 h before being warmed to rt. After stirring for an additional 1 h, the reaction was quenched with saturated aqueous NH_4Cl (2 mL). The biphasic solution was stirred for 1 h before being transferred to a separatory funnel where the phases were separated, and the aqueous phase was extracted with CH_2Cl_2 (3 x 5 mL). The combined organic phase was washed with 3 M NaOH (3 mL), was dried over MgSO_4 , filtered, and concentrated *in vacuo*. The resulting crude product was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g column and a gradient from 0-15% EtOAc in hexanes to afford **50** (41 mg, 0.105 mmol, 91%) as a white foam.


Data for Compound 50: For NMR Spectra of **50** see page S112. **TLC:** $R_f = 0.40$ (20% EtOAc in hexanes); **^1H NMR** (600 MHz, CDCl_3): δ 7.27 – 7.21 (m, 3H), 7.21 – 7.19 (m, 1H), 7.08 (d, $J = 7.5$ Hz, 2H), 6.79 (d, $J = 8.4$ Hz, 1H), 6.62 (s, 1H), 4.22 – 4.19 (m, 1H), 3.80 (s, 3H), 3.35 (s, 3H), 2.93 (dd, $J = 16.6, 4.9$ Hz, 1H), 2.82 – 2.76 (m, 2H), 2.56 (d, $J = 13.6$ Hz, 1H), 2.48 (dd, $J = 14.0, 5.2$ Hz, 1H), 2.43 – 2.35 (m, 4H), 2.10 (d, $J = 13.2$ Hz, 1H), 2.01 (app. t, $J = 13.6$ Hz, 1H), 1.89 (d, $J = 13.7$ Hz, 1H), 1.44 (app t, $J = 13.3$ Hz, 1H), 1.34 (s, 3H), 1.09 (dd, $J = 3.9, 8.5$ Hz, 1H); **$^{13}\text{C}\{^1\text{H}\}$ NMR** (150 MHz, CDCl_3): δ 157.0, 140.0, 139.0, 137.1, 136.1, 132.8, 130.4, 127.9, 127.1, 126.0, 113.0, 112.4, 80.0, 56.8, 55.1, 45.5, 43.9, 41.2, 38.2, 34.5, 33.8, 32.2, 31.6, 28.7, 25.0; **IR** (neat, cm^{-1}): 3025 (m), 2929 (m); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{33}\text{O}_2$ 389.2481; found, 389.2480; $[\alpha]_{589}^{21.0}$: -70.8 (c 1.495, CHCl_3).



Synthesis of S41: To a stirring solution of hydrindane **S26** (for preparation see page S16) (46 mg, 0.0811 mmol, 1.0 equiv) at 0 °C in CH₂Cl₂ (2 mL) was slowly added TFA (7 μ L, 0.094 mmol, 1.1 equiv). The reaction mixture was stirred at 0 °C for 5 h (reaction progress was monitored by TLC, 30% EtOAc in hexanes). Once reaction was complete by TLC the mixture was quenched with DI water (3 mL), followed by dilution with CH₂Cl₂ (5 mL), the biphasic solution was separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phases were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford the protodesilylated hydrindane as a clear oil which was immediately used in the next reaction.


To a stirring solution of the protodesilylated hydrindane in THF (2 mL) at 0 °C was added NaH in a 60% oil suspension (10 mg, 0.243 mmol, 3 equiv), and the solution was stirred for 10 min before the addition of MeI (30 μ L, 0.487 mmol, 6 equiv). The solution was warmed to rt and stirred overnight (~ 14 h). Upon completion, the reaction was cooled to 0 °C and quenched with a saturated aqueous solution of NaHCO₃ (3 mL), the phases were separated, and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford hydrindane **S41** as a clear oil (22.2 mg, 0.0436 mmol, 54% over two steps).


Data for Compound S41: For NMR Spectra of **S41** see page S114. **TLC:** R_f = 0.43 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.37 (s, 1H), 7.36 – 7.29 (m, 4H), 7.24 (d, *J* = 7.4 Hz, 2H), 7.22 – 7.17 (m, 2H), 7.09 – 7.04 (m, 2H), 6.79 (d, *J* = 7.5 Hz, 1H), 6.77 – 6.71 (m, 2H), 4.56 – 4.51 (m, 2H), 3.79 (s, 4H), 3.62 – 3.53 (m, 2H), 3.25 (s, 3H), 2.67 – 2.63 (m, 1H), 2.61 – 2.51 (m, 5H), 2.48 – 2.37 (m, 3H), 2.31 (dd, *J* = 12.6, 6.2 Hz, 1H), 2.15 (dd, *J* = 16.6, 6.5 Hz, 1H), 2.09 (dd, *J* = 18.0, 6.7 Hz, 1H), 1.92 (d, *J* = 16.6 Hz, 1H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 159.5, 143.6, 143.1, 138.7, 138.4, 134.5, 130.3, 129.2, 128.3, 128.1, 127.8, 127.6, 127.5, 125.9, 121.1, 120.9, 114.5, 111.0, 80.0, 73.0, 70.5, 56.8, 55.1, 44.4, 43.5, 38.4, 35.4, 35.2, 34.3, 32.9, 31.6; **IR** (neat, cm⁻¹): 3025 (m), 2926 (s), 2858 (m), 736 (m), 698 (m); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₃₅H₄₁O₃ 509.2977; found, 509.3056; [α]_D^{21.4}: -59.9 (*c* 0.105, CHCl₃).



Synthesis of 51: To a stirring solution of (*S*)-BINOL (11 mg, 0.039 mmol, 1.1 equiv) in CH₂Cl₂ (1 mL) at –78 °C was added SnCl₄ (0.035 mL, 0.035 mmol, 1.0 equiv, 1.0 M in CH₂Cl₂) which was stirred for 30 min at that temperature before the addition of **S41** (15 mg, 0.035 mmol, 1.0 equiv) in CH₂Cl₂ (1 mL), and the solution was kept at –40 °C for 2 h before being warmed to rt. After stirring for an additional 1 h, the reaction was quenched with saturated aqueous NH₄Cl (2 mL). The biphasic solution was stirred for 1 h before being transferred to a separatory funnel where the phases were separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 5 mL). The combined organic phase was washed with 3 M NaOH (3 mL), was dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting crude product was purified by flash chromatography with a Biotage® Snap Ultra 5 g column and a gradient from 0–15% EtOAc in hexanes to afford **51** (10 mg, 0.0196 mmol, 56%) as a white foam.

Data for Compound 51: For NMR Spectra of **51** see page S115. **TLC:** R_f = 0.40 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.32 – 7.26 (m, 6H), 7.20 (d, *J* = 8.2 Hz, 2H), 7.06 (d, *J* = 7.5 Hz, 2H), 6.73 (d, *J* = 8.6 Hz, 1H), 6.63 (s, 1H), 4.38 – 4.36 (m, 2H), 4.22 – 4.19 (m, 1H), 3.79 (s, 3H), 3.38 – 3.34 (m, 5H), 2.97 (td, *J* = 16.1, 5.4 Hz, 1H), 2.82 – 2.76 (m, 2H), 2.52 (d, *J* = 13.7 Hz, 1H), 2.48 – 2.45 (m, 2H), 2.37 – 2.32 (m, 4H), 2.05 – 1.97 (m, 3H) 1.87 (d, *J* = 13.7 Hz, 1H), 1.42 (app. t, *J* = 13.7 Hz, 1H), 1.08 (dd, *J* = 8.6, 3.8 Hz, 1H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 157.3, 139.0, 138.5, 137.8, 137.8, 137.6, 131.4, 130.4, 128.3, 127.9, 127.5, 127.4, 126.1, 113.2, 111.7, 79.8, 68.2, 56.9, 55.1, 45.3, 43.9, 41.2, 41.0, 40.2, 34.8, 31.3, 31.0, 28.8, 24.9; **IR** (neat, cm⁻¹): 2923 (m), 2851 (m); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₃₅H₄₁O₃ 509.2977; found, 509.3056; [α]_D^{21.4}: –19.9 (*c* 0.135, CHCl₃).






Synthesis of Hydrindane S42: To a stirring solution of hydrindane **S27** (for preparation see page S17) (215 mg, 0.426 mmol, 1.0 equiv) at 0 °C in CH₂Cl₂ (2 mL) was slowly added TFA (36 μL, 0.4686 mmol, 1.1 equiv). The reaction mixture was stirred at 0 °C for 30 mins (reaction progress was monitored by TLC, 30% EtOAc in hexanes). Once reaction was complete by TLC the mixture was quenched with DI water (5 mL), followed by dilution with CH₂Cl₂ (7 mL), the biphasic solution was separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phases were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage[®] Snap Ultra 10 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford the protodesilylated hydrindane as a clear oil which was immediately used in the next reaction.


To a stirring solution of the protodesilylated hydrindane in THF (2 mL) at 0 °C was added NaH in a 60% oil suspension (51 mg, 1.28 mmol, 3 equiv), and the solution was stirred for 10 min before the addition of MeI (159 μL, 2.56 mmol, 6 equiv). The solution was warmed to rt and stirred overnight (~ 14 h). Upon completion, the reaction was cooled to 0 °C and quenched with a saturated aqueous solution of NaHCO₃ (3 mL), the phases were separated, and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford hydrindane **S42** as a clear oil (137 mg, 0.306 mmol, 72% over two steps).


Data for Compound S42: For NMR Spectra of **S42** see page S117. **TLC:** R_f = 0.23 (10% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.37 – 7.31 (m, 4H), 7.30 – 7.27 (m, 1H), 7.19 (app. t, *J* = 7.8 Hz, 1H), 6.78 (d, *J* = 7.6 Hz, 1H), 6.75 – 6.69 (m, 2H), 5.34 (d, *J* = 5.5 Hz, 1H), 4.48 (s, 2H), 3.94 (m, 1H), 3.79 (s, 3H), 3.45 – 3.36 (m, 1H), 3.27 (s, 3H), 2.66 – 2.52 (m, 3H), 2.40 – 2.29 (m, 2H), 2.26 – 2.13 (m, 3H), 2.03 – 1.97 (m, 1H), 1.80 (s, 3H), 1.55 – 1.40 (m, 3H), 1.31 (dd, *J* = 12.4, 8.4 Hz, 1H), 1.12 – 1.05 (m, 1H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 159.6, 143.9, 142.4, 138.7, 133.1, 129.3, 128.4, 128.2, 127.7, 127.6, 121.0, 119.6, 114.6, 111.0, 80.5, 73.0, 71.2, 56.9, 55.2, 44.4, 43.2, 35.7, 34.7, 34.2, 31.8, 29.7, 25.5, 19.4; **IR** (neat, cm⁻¹): 2936 (s), 2859 (m), 779 (w), 737 (m), 697 (m); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₃₀H₃₉O₃ 447.2899; found, 447.2894; [α]_D^{22.4}: –133.8 (*c* 0.00014, CHCl₃).



Synthesis of Tetracycle 52: To a stirring solution of (*S*)-BINOL (36 mg, 0.104 mmol, 1.2 equiv) in CH₂Cl₂ (1.1 mL) at $-78\text{ }^{\circ}\text{C}$ was added SnCl₄ (0.104 mL, 0.104 mmol, 1.0 equiv, 1.0 M in CH₂Cl₂) which was stirred for 30 min at that temperature before the addition of **S42** (46.6 mg, 0.104 mmol, 1.0 equiv) in CH₂Cl₂ (1.0 mL), and the solution was kept at that temperature for 15 min before being transferred to a $-40\text{ }^{\circ}\text{C}$ bath. The reaction mixture was stirred for 2 h at $-40\text{ }^{\circ}\text{C}$ before being warmed to rt. After stirring for an additional 1 h, the reaction was quenched with saturated aqueous NH₄Cl (2 mL). The biphasic solution was stirred for 1 h before being transferred to a separatory funnel where the phases were separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phase was washed with 5 mol% NaOH (1 mL), was dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting crude product was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g column and a gradient from 0-5% EtOAc in hexanes to afford **52** (32.5 mg, 0.0728 mmol, 70%) as a clear oil.

Data for Compound 52: For NMR Spectra of **52** see page S118. **TLC:** $R_f = 0.20$ (10% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.37 – 7.25 (m, 5H), 7.21 (d, $J = 8.6$ Hz, 1H), 6.77 (d, $J = 8.5$ Hz, 1H), 6.60 (s, 1H), 4.47 (s, 2H), 4.07 – 4.05 (m, 1H), 3.79 (s, 3H), 3.24 – 3.35 (m, 2H), 3.33 (s, 3H), 2.90 (dd, $J = 15.8, 2.9$ Hz, 1H), 2.81 – 2.69 (m, 2H), 2.48 – 2.42 (m, 1H), 2.41 – 2.30 (m, 3H), 2.04 (d, $J = 13.2$ Hz, 1H), 1.92 (d, $J = 13.3$ Hz, 1H), 1.80 (app. t, $J = 13.6$ Hz, 1H), 1.59 – 1.50 (m, 3H), 1.33 (s, 3H), 1.32 – 1.24 (m, 1H), 1.21 – 1.13 (m, 2H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 157.1, 140.2, 138.6, 137.3, 136.7, 131.9, 128.4, 127.6, 127.2, 113.0, 112.5, 80.1, 73.0, 71.0, 56.9, 55.2, 44.1, 44.0, 38.0, 34.4, 34.0, 32.3, 31.8, 31.5, 29.0, 25.0, 25.0; **IR** (neat, cm⁻¹): 2932 (s), 2859, 736 (w), 698 (w); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for C₃₀H₃₉O₃ 447.2899; found, 447.2892; $[\alpha]_{589}^{22.6}$: -97.1 (c 0.0019, CHCl₃).






Synthesis of Hydrindane S43: To a stirring solution of hydrindane **S29** (for preparation see page S18) (50 mg, 0.086 mmol, 1.0 equiv) at 0 °C in CH₂Cl₂ (2 mL) was slowly added TFA (7.2 μL, 0.095 mmol, 1.1 equiv). The reaction mixture was stirred at 0 °C for 2 h (reaction progress was monitored by TLC, 30% EtOAc in hexanes). Once reaction was complete by TLC the mixture was quenched with DI water (3 mL), followed by dilution with CH₂Cl₂ (5 mL), the biphasic solution was separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phases were dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford the protodesilylated hydrindane as a clear oil which was immediately used in the next reaction.


To a stirring solution of the protodesilylated hydrindane in THF (2 mL) at 0 °C was added NaH in a 60% oil suspension (10.5 mg, 0.258 mmol, 3 equiv), and the solution was stirred for 10 min before the addition of MeI (32 μL, 0.516 mmol, 6 equiv). The solution was warmed to rt and stirred overnight (~ 14 h). Upon completion, the reaction was cooled to 0 °C and quenched with a saturated aqueous solution of NaHCO₃ (3 mL), the phases were separated, and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic phase was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting crude oil was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g cartridge and a gradient from 0–15% EtOAc in hexanes to afford hydrindane **S43** as a clear oil (24 mg, 0.0459 mmol, 53% over two steps).

Data for S43: For NMR Spectra of **S43** see page S120. **TLC:** R_f = 0.15 (30% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.37 – 7.31 (m, 4H), 7.31 – 7.27 (m, 1H), 7.24 – 7.20 (m, 2H), 7.19 – 7.13 (m, 4H), 6.74 – 6.68 (m, 2H), 6.63 (s, 1H), 5.37 (d, *J* = 6.6 Hz, 1H), 4.50 (s, 3H), 3.93 (app. p, *J* = 7.2 Hz, 1H), 3.78 (s, 3H), 3.50 – 3.36 (m, 4H), 3.27 (s, 3H), 2.64 (dd, *J* = 18.0, 7.3 Hz, 1H), 2.55 – 2.48 (m, 1H), 2.46 – 2.39 (m, 1H), 2.33 – 2.21 (m, 4H), 2.17 (dd, *J* = 18.0, 6.2 Hz, 1H), 2.08 (d, *J* = 16.5 Hz, 1H), 1.55 – 1.47 (m, 3H), 1.35 (dd, *J* = 12.8, 8.4 Hz, 1H), 1.22 – 1.15 (m, 1H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 159.6, 143.9, 143.6, 140.7, 138.7, 136.4, 129.5, 129.4, 129.3, 128.8, 128.5, 128.4, 128.1, 128.0, 127.7, 127.6, 126.0, 122.1, 121.0, 114.5, 111.1, 80.5, 73.1, 71.2, 56.9, 55.3, 44.4, 43.1, 39.5, 35.6, 35.0, 34.5, 31.7, 29.7, 25.6; **IR** (neat, cm⁻¹): 2924 (s), 2854 (m); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₃₆H₄₃O₃ 523.3212; found, 523.3192; [α]_D^{22.3}: -13.9 (*c* 0.0006, CHCl₃).




Synthesis of Tetracycle 53: To a stirring solution of (*S*)-BINOL (11.0 mg, 0.0358 mmol, 1.1 equiv) in CH₂Cl₂ (1 mL) at -78 °C was added SnCl₄ (33 μL, 0.0325 mmol, 1.0 equiv, 1.0 M in CH₂Cl₂) which was stirred for 30 min at that temperature before the addition of **S43** (17 mg, 0.0325 mmol, 1.0 equiv) in CH₂Cl₂ (1 mL), and the solution was kept at that temperature for 15 min before being transferred to a -40 °C bath. The reaction mixture was the stirred for 2 h at -40 °C before being warmed to rt. After stirring for an additional 1 h, the reaction was quenched with saturated aqueous NH₄Cl (2 mL). The biphasic solution was stirred for 1 h before being transferred to a separatory funnel where the phases were separated, and the aqueous phase was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic phase was washed with 2 M NaOH (1 mL), was dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting crude product was purified by flash chromatography with a Biotage[®] Snap Ultra 5 g column and a gradient from 0-15% EtOAc in hexanes to afford **53** (11 mg, 0.00210 mmol, 65%) as a clear oil.

Data for Compound 53: For NMR Spectra of **53** see page S121. **TLC:** R_f = 0.22 (20% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.32 – 7.22 (m, 5H), 7.15 (app s, 3H), 6.78 (app s, 2H), 6.68 (d, *J* = 8.5 Hz, 1H), 6.62 – 6.57 (m, 2H), 4.41 (s, 2H), 4.04 – 3.98 (m, 1H), 3.77 (s, 3H), 3.36 – 3.28 (m, 5H), 3.03 – 2.95 (m, 2H), 2.84 (d, *J* = 13.6 Hz, 1H), 2.82 – 2.75 (m, 2H), 2.55 – 2.44 (m, 2H), 2.33 (dd, *J* = 16.7, 4.4 Hz, 1H), 2.23 (dd, *J* = 11.8, 6.3 Hz, 1H), 2.13 (d, *J* = 13.6 Hz, 1H), 1.72 – 1.56 (m, 2H), 1.49 – 1.43 (m, 2H), 1.23 – 1.16 (m, 1H), 1.14 – 1.06 (m, 2H), 1.00 – 0.95 (m, 1H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 157.3, 139.1, 139.0, 138.6, 137.7, 137.6, 130.8, 130.1, 128.5, 128.4, 127.7, 127.7, 127.6, 127.6, 126.1, 112.9, 111.5, 79.9, 73.0, 70.9, 56.9, 55.2, 47.3, 43.8, 42.3, 34.8, 34.9, 31.5, 30.2, 28.4, 24.9, 24.8; **IR** (neat, cm⁻¹): 2931 (s), 2860 (m), 736 (w), 700 (s); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₃₆H₄₃O₃ 523.3212; found, 523.3210; [α]₅₈₉^{22.5}: -121.2 (*c* 0.0004, CHCl₃).




G. Synthesis of Tetracycle from Hajos–Parrish Ketone Derivative



Synthesis of Alkylated Hydrindane S46: To a stirring solution of TBS-protected Hajos–Parrish ketone **S44**¹² (508.7 mg, 1.8 mmol, 1.0 equiv) in DME (1.8 mL) was added NaH (60% dispersion in mineral oil, 108.9 mg, 2.7 mmol, 1.5 equiv) at rt. The reaction mixture was heated in an oil bath to 65 °C and let stir for 20 h. After, tosylate **S45** (611.2 mg, 2.0 mmol, 1.1 equiv) was dissolved in DME (1.8 mL) and added dropwise to the reaction mixture over 15 min at 65 °C. The reaction mixture was let stir for 1 h at 65 °C and then cooled to 0 °C and quenched by the addition of a saturated aqueous solution of NaH₂PO₄ (2 mL). The reaction mixture was warmed to rt before the two phases were separated, and the aqueous phase was extracted with CH₂Cl₂. The combined organic phase was washed with brine and dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude concentrate was purified by flash chromatography with a Biotage® Sfär Silica HC D 50 g column and a gradient from 0–12% EtOAc in hexanes with an additive of 5% CH₂Cl₂ to afford alkylated hydrindane **S46** (388.7 mg, 0.9 mmol, 52%) as a yellow oil.



Data for Compound S46: For NMR Spectra of **S46** see page S122. **TLC:** R_f = 0.32 (10% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.16 (app. t, *J* = 7.8 Hz, 1H), 6.73 – 6.71 (m, 2H), 6.66 (s, 1H), 3.78 (s, 3H), 3.59 (dd, *J* = 7.6, 7.9 Hz, 1H), 2.62 (app. t, *J* = 7.4 Hz, 2H), 2.60 – 2.51 (m, 1H), 2.46 – 2.36 (m, 3H), 2.20 – 2.10 (m, 1H), 2.06 – 1.95 (m, 2H), 1.82 – 1.74 (m, 1H), 1.71 – 1.60 (m, 2H), 1.01 (s, 3H), 0.89 (s, 9H), 0.03 (d, *J* = 3.5 Hz, 6H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 198.6, 169.4, 159.6, 143.9, 132.1, 129.2, 121.5, 114.8, 111.2, 81.0, 55.3, 45.7, 34.8, 34.3, 33.8, 29.9, 27.9, 25.9, 25.2, 18.2, 15.5, –4.3, –4.8; **IR** (neat, cm⁻¹): 2957 (s), 2925 (s), 2860 (m), 1658 (s), 868 (w), 837 (m), 781 (m); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₂₅H₃₉O₃Si 415.2668; found, 415.2661; [α]_D^{22.1}: +18.4 (*c* = 0.85, CHCl₃).



Synthesis of alcohol 54: To a stirring solution of alkylated hydrindane **S46** (132.8 mg, 0.3 mmol, 1.0 equiv) in THF (2.9 mL) was added MeMgBr (0.2 mL, 0.6 mmol, 2.0 equiv, 3.1 M in diethyl ether) dropwise at –30 °C. The reaction mixture was stirred at –30 °C for 2 h and then warmed to rt. After stirring at rt for 23 h, the reaction mixture was quenched by the slow addition of a saturated aqueous solution of NH₄Cl (0.5 mL). H₂O (1 mL) was added, the two phases were separated, and the aqueous phase was extracted with EtOAc. The combined organic phase was washed with brine and dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude concentrate was purified by

flash chromatography with a Biotage® Sfär Silica HC D 25 g column. The column was deactivated with a 5% triethylamine in hexanes (by volume) solution before use and then purification was done with a gradient from 5–20% EtOAc in hexanes to afford alcohol **54** (125.5 mg, 0.3 mmol, 91%) as a colorless oil. There was no detectable presence of the other diastereomer in the ¹H NMR of the crude material.


Data for Compound 54: For NMR Spectra of **54** see page S123. **TLC:** R_f = 0.28 (15% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.20 (app. t, *J* = 8.1 Hz, 1H), 6.79 (d, *J* = 7.5 Hz, 1H), 6.74 (d, *J* = 6.4 Hz, 2H), 3.80 (s, 3H), 3.52 (dd, *J* = 9.8, 7.8 Hz, 1H), 2.75 – 2.61 (m, 2H), 2.41 – 2.34 (m, 1H), 2.34 – 2.25 (m, 2H), 2.18 – 2.13 (m, 1H), 1.88 (ddd, *J* = 17.2, 12.9, 7.8 Hz, 1H), 1.81 (dd, *J* = 14.5, 2.6 Hz, 1H), 1.77 – 1.65 (m, 3H), 1.32 (app. t, *J* = 13.0 Hz, 1H), 1.22 (s, 3H), 0.99 (s, 3H), 0.89 (s, 9H), 0.03 (s, 6H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 159.8, 144.5, 142.2, 134.4, 129.4, 121.2, 114.6, 111.3, 81.6, 73.8, 55.3, 45.0, 37.6, 36.3, 34.2, 30.5, 29.8, 27.7, 26.0, 24.1, 18.2, 17.4, –4.2, –4.6; **IR** (neat, cm⁻¹): 3451 (br), 2957 (s), 2933 (s), 2846 (m), 838 (s), 786 (m); **HRMS** (ESI-TOF) (*m/z*): [M-OH]⁺ calcd for C₂₆H₄₁O₂Si 413.2876; found, 413.2867; [α]_D²²: +14.0 (c = 0.23, CHCl₃).




Synthesis of Tetracycles 55 and S47: To a stirring solution of alcohol **54** (72.6 mg, 0.2 mmol, 1.0 equiv) in CH₂Cl₂ (1.7 mL) was added BF₃•OEt₂ (62.3 μL, 0.5 mmol, 3.0 equiv) dropwise at –78 °C. The reaction mixture was stirred at –78 °C for 15 min and then warmed to –30 °C and quenched by the addition of saturated aqueous NaHCO₃ (2 mL). The reaction mixture was let warm to rt before the two phases were separated, and the aqueous phase was extracted with CH₂Cl₂. The combined organic phase was washed with water and brine then dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude concentrate was purified by flash chromatography with a Biotage® Sfär Silica HC Duo 10 g column and a gradient from 0–10% EtOAc in hexanes to afford tetracycles **55** and **S47** (57.0 mg, 0.1 mmol, 82%, d.r. 18:1 **54**:**S47**) as an inseparable mixture of yellow oils.

Data for Compound 55: For NMR Spectra of **55** see page S124. **TLC:** R_f = 0.62 (10% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.21 (d, *J* = 8.6 Hz, 1H), 6.76 (dd, *J* = 8.7, 2.8 Hz, 1H),



6.57 (s, 1H), 3.77 (s, 3H), 3.62 (dd, $J = 9.7, 7.8$ Hz, 1H), 2.85 (ddd, $J = 16.1$ Hz, 5.9, 2.6 Hz, 1H), 2.71 (ddd, $J = 16.4, 12.3, 5.7$ Hz, 1H), 2.46 (ddd, $J = 13.1, 5.8, 2.6$ Hz, 1H), 2.36 – 2.21 (m, 3H), 2.10 – 2.07 (m, 1H), 1.94 – 1.88 (m, 1H), 1.88 – 1.80 (m, 1H), 1.74 – 1.65 (m, 2H), 1.52 – 1.44 (m, 1H), 1.29 (s, 3H), 0.91 (s, 9H), 0.84 (s, 3H), 0.06 (d, $J = 7.9$ Hz, 6H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 157.1, 140.3, 137.4, 136.0, 132.9, 127.4, 113.1, 112.5, 82.1, 55.3, 44.2, 38.4, 34.7, 32.3, 32.1, 31.4, 30.6, 26.0, 24.1, 23.8, 18.2, 17.7, -4.2, -4.6; IR (neat, cm^{-1}): 2964 (s), 2925 (s), 2857 (s), 840 (s), 809 (w), 774 (s); HRMS (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{41}\text{O}_2\text{Si}$ 413.2876; found, 413.2861; $[\alpha]_{589}^{21.9}$: +98.5 ($c = 0.295$, CHCl_3).




Data for Compound S47: For NMR Spectra of **S47** see page S125. TLC: $R_f = 0.62$ (10% EtOAc in hexanes); ^1H NMR (500 MHz, CDCl_3): δ 7.25 (s, 1H), 6.73 (dd, $J = 8.6, 2.8$ Hz, 1H), 6.57 (d, $J = 2.8$ Hz, 1H), 3.77 (s, 3H), 3.46 (dd, $J = 9.9, 7.6$ Hz, 1H), 2.86 – 2.71 (m, 2H), 2.48 (ddd, $J = 13.3, 6.0, 3.0$ Hz, 1H), 2.38 – 2.30 (m, 2H), 2.26 – 2.20 (m, 1H), 2.12 – 2.03 (m, 1H), 1.88 (ddd, $J = 14.2, 11.0, 3.7$ Hz, 1H), 1.84 – 1.76 (m, 1H), 1.72 – 1.64 (m, 1H), 1.61 – 1.55 (m, 1H), 1.33 (s, 3H), 1.22 – 1.13 (m, 1H), 0.97 (s, 3H), 0.87 (s, 9H), -0.03 (d, $J = 6.6$ Hz, 6H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 157.2, 139.1, 138.6, 136.6, 134.3, 126.5, 113.6, 112.0, 80.4, 55.2, 43.8, 39.2, 34.4, 32.3, 32.0, 31.7, 30.2, 26.0, 24.1, 23.8, 18.4, 18.2, -4.3, -4.7; IR (neat, cm^{-1}): 3410 (br), 2961 (s), 2926 (s), 2853 (s), 834 (s), 768 (m); HRMS (ESI-TOF) (m/z): $[\text{M}-\text{C}_6\text{H}_{15}\text{OSi}]^+$ calcd for $\text{C}_{20}\text{H}_{25}\text{O}$ 281.1905; found, 281.1895; $[\alpha]_{589}^{20.9}$: -94.9 ($c = 0.49$, CHCl_3).



^1H NMR (600 MHz, CDCl_3) of crude material containing **55** and **S47**




H. Synthesis of C9,C13-Syn-Substituted Tetracycles and Oxidative Shift




Synthesis of Tetracycle 57: A flask containing $\text{Pd}_2(\text{dba})_3$ (79 mg, 0.087 mmol, 0.20 equiv) and *rac*-BINAP (215 mg, 0.346 mmol, 0.80 equiv) was sparged with N_2 for 5 min before the addition of **56**⁶ (199 mg, 0.432 mmol, 1.0 equiv) in PhMe (17 mL). 1,2,2,6,6-pentamethylpiperidine (PMP) (0.310 mL, 1.73 mmol, 4.0 equiv) was added, the N_2 inlet was removed from the septum, and vinyl tape was used to further seal the flask prior to partial immersion in a pre-heated oil bath at 110 °C until the reaction was deemed complete by TLC analysis. Upon completion, the flask was cooled to rt and concentrated *in vacuo*. The crude residue was then purified by flash chromatography using a gradient of 0-30% EtOAc in hexanes to afford **57** (23 mg, 0.074 mmol, 85%) as a clear oil.

Data for Compound 57: For NMR Spectra of **57** see page S126. **TLC:** $R_f = 0.30$ (30% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl_3): δ 7.28 (d, $J = 8.7$ Hz, 1H), 6.76 (app. dd, $J = 8.7, 2.9$ Hz, 1H), 6.58 (d, $J = 2.8$ Hz, 1H), 5.88 (d, $J = 9.8$ Hz, 1H), 5.80 (d, $J = 9.8$ Hz, 1H), 4.58 – 4.52 (m, 1H), 3.77 (s, 3H), 2.93 (ddd, $J = 16.4, 8.4, 2.0$ Hz, 1H), 2.81 (dd, $J = 8.4, 3.7$ Hz, 2H), 2.54 (dt, $J = 13.5, 4.2$ Hz, 1H), 2.40 (dd, $J = 16.4, 3.8$ Hz, 1H), 2.32 – 2.24 (m, 1H), 2.08 (dd, $J = 12.3, 6.8$ Hz, 1H), 1.86 – 1.78 (m, 1H), 1.67 (dq, $J = 14.6, 7.4$ Hz, 1H), 1.43 (s, 1H), 1.38 (dd, $J = 12.3, 7.1$ Hz, 1H), 1.11 (s, 3H), 0.80 (t, $J = 7.5$ Hz, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl_3): δ 157.1, 137.9, 137.0, 136.6, 132.8, 131.2, 129.1, 127.6, 113.5, 112.4, 70.4, 55.2, 49.6, 45.0, 42.6, 37.3, 36.8, 31.6, 28.2, 25.2, 10.7; **IR** (neat, cm^{-1}): 3359 (b), 2957 (m), 1708 (s), 813 (m), 750 (m); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{27}\text{O}_2$ 311.2011; found, 311.2003; $[\alpha]_{\text{D}}^{20.9}$: -95.1 (c 0.0013, CHCl_3).



Synthesis of Tetracycle 59: A flask containing $\text{Pd}_2(\text{dba})_3$ (25 mg, 0.027 mmol, 0.20 equiv) and *rac*-BINAP (68 mg, 0.110 mmol, 0.80 equiv) was sparged with N_2 for 5 min before the addition of **58**⁶ (72 mg, 0.137 mmol, 1.0 equiv) in PhMe (5.5 mL). 1,2,2,6,6-pentamethylpiperidine (PMP) (0.099 mL, 0.055 mmol, 4.0 equiv) was added, the N_2 inlet was removed from the septum, and vinyl tape was used to further seal the flask prior to partial immersion in a pre-heated oil bath at 110 °C until the reaction was deemed complete by TLC analysis. Upon completion, the flask was cooled to rt and concentrated *in vacuo*. The crude residue was then purified by flash chromatography using a gradient of 0-30% EtOAc in hexanes to afford **59** (6.0 mg, 0.016 mmol, 58%) as a clear oil.


Data for Compound 59: For NMR Spectra of **59** see page S127. **TLC:** R_f = 0.30 (30% EtOAc in hexanes); **¹H NMR** (600 MHz, CDCl₃): δ 7.32 (d, *J* = 8.7 Hz, 1H), 7.19 – 7.09 (m, 3H), 6.95 – 6.92 (m, 2H), 6.78 (dd, *J* = 8.7, 2.8 Hz, 1H), 6.59 (d, *J* = 2.8 Hz, 1H), 5.99 (d, *J* = 9.8 Hz, 1H), 5.69 (d, *J* = 9.8 Hz, 1H), 4.47 – 4.41 (m, 1H), 3.78 (s, 3H), 3.15 (d, *J* = 13.2 Hz, 1H), 2.89 (d, *J* = 13.2 Hz, 1H), 2.86 – 2.77 (m, 3H), 2.55 (dt, *J* = 13.4, 4.1 Hz, 1H), 2.35 (dd, *J* = 16.5, 3.9 Hz, 1H), 2.27 – 2.19 (m, 1H), 1.95 (dd, *J* = 12.3, 6.7 Hz, 1H), 1.30 (dd, *J* = 12.3, 7.2 Hz, 1H), 1.26 – 1.24 (m, 1H), 0.28 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 157.5, 138.7, 138.3, 137.7, 135.9, 133.3, 131.0, 131.0, 128.6, 128.3, 127.5, 126.3, 113.6, 112.6, 70.5, 55.4, 50.6, 49.6, 46.6, 42.7, 37.4, 31.8, 26.7, 25.5; **IR** (neat, cm⁻¹): 3411 (b), 3026 (s), 2923 (m), 1712 (s), 845 (m), 803 (m), 745 (m), 701 (m); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₂₆H₂₉O₂ 373.2168; found, 373.2161; [α]_D^{20.9}: -31.0 (*c* 0.0011, CHCl₃).



Synthesis of Tetracycle 60: To a stirring solution of **29** (for preparation see page S28) (100 mg, 0.338 mmol, 1.0 equiv) in toluene (4 mL) was added DIBAL-H (1.0 M in hexanes, 3.4 mL, 3.40 mmol, 10 equiv) at rt under N₂ atmosphere. The resulting mixture was heated in an oil bath to 100 °C and refluxed overnight (approx. 12 h). When the reaction was complete, as judged by TLC analysis, the reaction mixture was cooled to 0 °C where it was quenched slowly with ice then 2 M HCl (5 mL). The biphasic solution was separated, and the aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic phases were dried over MgSO₄, filtered, and concentrated *in vacuo* to afford the crude product as an amorphous yellow oil.


The crude residue was then diluted with 4 ml EtOAc under an atmosphere of N₂ at rt. Pd/C (10 mg, 10% by mass) was then added to the solution. The atmosphere of N₂ was exchanged for H₂ by bubbling H₂ gas into the reaction mixture. The reaction mixture was stirred under a positive pressure of H₂ overnight (approx. 12 h) before the solution was filtered and concentrated *in vacuo*. The resulting crude residue was purified by flash chromatography with a Biotage® Snap Ultra 5 g column and a gradient from 10-30% EtOAc in CH₂Cl₂ to afford **60** (0.87 g, 0.308 mmol, 91% over 2 steps) as a crystalline solid.

Data for Compound 60: For NMR Spectra of **60** see page S128. **¹H NMR** (600 MHz, CDCl₃): δ 7.19 (d, *J* = 8.5 Hz, 1H), 6.64 (dd, *J* = 8.5, 2.9 Hz, 1H), 6.50 – 6.49 (m, 1H), 4.59 – 4.53 (m, 1H), 2.88 – 2.82 (m, 1H), 2.81 – 2.76 (m, 2H), 2.46 – 2.43 (dt, *J* = 13.4, 4.6 Hz, 1H), 2.39 – 2.33 (m, 1H), 2.29 (dd, *J* = 16.7, 5.1 Hz, 1H), 2.21 (ddd, *J* = 14.2, 5.7, 3.5 Hz, 1H), 2.02 (dd, *J* = 12.1, 6.5 Hz, 1H), 1.90 (ddd, *J* = 14.2, 12.3, 3.5 Hz, 1H), 1.59 – 1.54 (m, 1H), 1.32 (s, 3H), 1.28 – 1.21 (m, 2H), 1.04 (s, 3H); **¹³C{¹H} NMR** (150 MHz, CDCl₃): δ 153.1, 139.0, 138.9, 137.0, 133.5, 126.6, 115.2, 113.2, 71.1, 51.4, 41.3, 39.0, 38.0, 34.3, 34.1, 32.9, 31.6, 25.9, 24.7; **IR** (neat, cm⁻¹): 3597 (s), 2956 (b), 2930 (b), 2861 (m); **HRMS** (ESI-TOF) (*m/z*): [M+H]⁺ calcd for C₁₉H₂₅O₂ 285.1855; found, 285.1844. [α]_D^{22.4}: -18.2 (*c* 0.0030, CHCl₃).



Synthesis of Tetracycle 61: To a stirring solution of **35**⁷ (0.17 g, 0.57 mmol, 1.0 equiv) in toluene (5 mL) at rt under N₂ atmosphere was added DIBAL-H (1.0 M in hexanes, 5.7 mL, 5.7 mmol, 10 equiv). The resulting mixture was heated in an oil bath to 100 °C and refluxed overnight (approx. 20 h). When the reaction was complete, as judged by TLC analysis, the reaction mixture was cooled to 0 °C where it was quenched slowly with ice then 2 M HCl (5 mL). The biphasic solution was separated, and the aqueous phase was extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over Na₂SO₄, filtered, and then the filtrate was concentrated *in vacuo*. The resulting crude product was purified by flash chromatography with a Biotage® Snap Ultra 10 g column and a gradient from 10-30% EtOAc in CH₂Cl₂ to afford **61** (0.15 g, 0.54 mmol, 94% isolated yield) as an amorphous white solid.


Data for Compound 61: For NMR Spectra of **61** see page S129. ¹H NMR (500 MHz, MeOD) δ 7.09 (d, *J* = 8.6 Hz, 1H), 6.60 (dd, *J* = 8.5, 2.7 Hz, 1H), 6.44 (d, *J* = 2.6 Hz, 1H), 4.55 – 4.52 (m, 1H), 2.87 – 2.77 (m, 2H), 2.61 (ddd, *J* = 15.9, 11.8, 5.7 Hz, 1H), 2.41 (ddd, *J* = 12.8, 5.7, 2.5 Hz, 1H), 2.32 (td, *J* = 13.4, 12.8, 5.1 Hz, 1H), 2.23 (dd, *J* = 16.9, 4.5 Hz, 1H), 2.12 – 2.04 (m, 2H), 1.79 (td, *J* = 12.8, 4.0 Hz, 1H), 1.74 – 1.63 (m, 2H), 1.34 – 1.26 (m, 4H), 0.89 (s, 3H); ¹³C{¹H} NMR (150 MHz, MeOD) δ 155.4, 140.0, 138.0, 137.5, 133.2, 128.1, 115.4, 114.6, 71.7, 52.4, 42.5, 39.0, 38.0, 35.5, 34.4, 33.0, 31.7, 26.1, 26.0; IR (thin film, cm⁻¹): 3314, 2932, 2857, 737; HRMS (ESI-TOF): calcd for C₁₉H₂₅O₂ [M+H]⁺ 285.1855, found 285; [α]_D^{20.9}; -229.4 (*c* 0.024, MeOH).



Synthesis of Tetracycle 63: A solution of tetracycle **62** (for preparation see page S30) (24 mg, 0.0791 mmol, 1.0 equiv) in HFIP (2 mL) at 0 °C under N₂ atmosphere was stirred for 10 min before the addition of PIDA (24 mg, 0.0751 mmol, 0.95 equiv). The solution was stirred for no more than 1 min before being quenched with saturated aqueous NaHCO₃ (1 mL). HFIP was subsequently removed from the reaction mixture under vacuum, and the mostly aqueous remains was diluted with EtOAc (2 mL). The organic phase was separated, the aqueous phase was extracted with 3 x 20 mL EtOAc, and the combined organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo*. The resulting crude product was purified by flash chromatography using a gradient of 20–60% EtOAc in hexanes to afford **63** (13 mg, 0.0443 mmol, 56%) as a white solid.


Data for Compound 63: For NMR Spectra of **63** see page S130. TLC: R_f = 0.23 (45% EtOAc in 45% hexanes with 10% CH₂Cl₂); ¹H NMR (600 MHz, CDCl₃): δ 7.10 (d, *J* = 1.03 Hz, 1H), 6.38 (dd, *J* = 11.0, 1.8 Hz, 1H), 6.24 (s, 1H), 5.44 (s, 1H), 5.06 – 5.03 (m, 1H), 4.43 – 4.36 (m, 1H), 2.66 – 2.49 (m, 5H), 2.37 – 2.28 (m, 2H), 2.10 – 2.05 (m, 1H), 1.90 – 1.76 (m, 4H), 1.55 – 1.49 (m, 1H), 1.36 (dd, *J* = 12.5, 7.3 Hz, 1H), 1.00 (s, 3H), 0.60 (t, *J* = 7.5 Hz, 3H); ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 186.2, 164.1, 152.1, 150.5, 138.3, 130.5, 125.8, 125.1, 124.1, 76.5, 51.6,

49.5, 43.4, 35.9, 33.9, 30.0, 29.5, 29.1, 24.5, 24.0, 8.1; **IR** (neat, cm^{-1}): 3383 (m), 2925 (s), 2853 (s), 1662 (s), 887 (m), 816 (w), 754 (m); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{25}\text{O}_2$ 297.1855; found, 297.1849; $[\alpha]_{589}^{20.9}$: -39.6 (c 0.0008, CHCl_3).



Synthesis of Tetracycle 64: A solution of tetracycle **38** (for preparation see page S30) (21 mg, 0.0704 mmol, 1.0 equiv) in HFIP (2 mL) at 0 °C under N_2 atmosphere was stirred for 10 min before the addition of PIDA (22 mg, 0.0669 mmol, 0.95 equiv). The solution was stirred for no more than 1 min before being quenched with saturated aqueous NaHCO_3 (2 mL). HFIP was subsequently removed from the reaction mixture under vacuum, and the mostly aqueous remains was diluted with EtOAc (2 mL). The organic phase was separated, the aqueous phase was extracted with 3 x 20 mL EtOAc, and the combined organic phase was dried over MgSO_4 , filtered, and concentrated *in vacuo*. The resulting crude product was purified by flash chromatography using a gradient of 20–60% EtOAc in hexanes to afford **64** (18 mg, 0.061 mmol, 86%) as a white solid.


Data for Compound 64: For NMR Spectra of **64** see page S131. **TLC:** R_f = 0.09 (45% EtOAc in 45% hexanes with 10% CH_2Cl_2); **^1H NMR** (600 MHz, CDCl_3): δ 7.01 (d, J = 10.2 Hz, 1H), 6.37 (d, J = 9.9 Hz, 1H), 6.24 (s, 1H), 5.49 (s, 1H), 5.08 – 5.05 (m, 1H), 2.80 – 2.71 (m, 1H), 2.62 – 2.53 (m, 1H), 2.52 – 2.42 (m, 2H), 2.37 – 2.21 (m, 3H), 2.09 – 2.04 (m, 2H), 1.88 – 1.78 (m, 2H), 1.62 – 1.54 (m, 1H), 1.43 – 1.35 (m, 1H), 0.88 (s, 3H), 0.59 (t, J = 7.4 Hz, 3H); **$^{13}\text{C}\{^1\text{H}\}$ NMR** (150 MHz, CDCl_3): δ 186.3, 164.4, 151.1, 149.7, 137.9, 130.6, 125.8, 124.7, 124.5, 76.4, 51.5, 49.3, 43.2, 36.2, 32.9, 29.4, 29.0, 25.0, 23.5, 8.1; **IR** (neat, cm^{-1}): 3389 (s), 2924 (s), 2853 (s), 1734 (w), 1661 (s); **HRMS** (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{25}\text{O}_2$ 297.1855; found, 297.1845; $[\alpha]_{589}^{20.9}$: -14.8 (c 0.0005, CHCl_3).



Synthesis of Tetracycle 65: A solution of tetracycle **40** (for preparation see page S33) (18 mg, 0.064 mmol, 1.0 equiv) in HFIP (2 mL) at 0 °C under N_2 atmosphere was stirred for 10 min before the addition of PIDA (20 mg, 0.061 mmol, 0.95 equiv). The solution was stirred for no more than 1 min before being quenched with saturated aqueous NaHCO_3 (2 mL). HFIP was subsequently removed from the reaction mixture under vacuum, and the mostly aqueous remains was diluted with EtOAc (2 mL). The organic phase was separated, the aqueous phase was extracted with 3 x 20 mL EtOAc, and the combined organic phase was dried over MgSO_4 , filtered, and concentrated *in vacuo*. The resulting crude product was purified by flash chromatography using a gradient of 20–60% EtOAc in hexanes to afford **65** (11 mg, 0.040 mmol, 63%) as a white solid.

Data for Compound 65: For NMR Spectra of **65** see page S132. **TLC:** R_f = 0.16 (45% EtOAc in 45% hexanes with 10% CH_2Cl_2); **^1H NMR** (600 MHz, CDCl_3): δ 7.19 – 7.13 (m, 4H), 6.98 – 6.90

(m, 2H), 6.16 (dd, $J = 11.1, 1.4$ Hz, 1H), 6.06 (s, 1H), 5.55 (s, 1H), 5.10 – 5.08 (m, 1H), 3.26 (d, $J = 13.4$ Hz, 1H), 3.11 (d, $J = 13.4$ Hz, 1H), 2.92 – 2.80 (m, 2H), 2.59 – 2.54 (m, 1H), 2.49 (d, $J = 17.5$ Hz, 1H), 2.39 – 2.26 (m, 3H), 1.84 (dd, $J = 12.4, 4.1$ Hz, 1H), 1.68 – 1.55 (m, 2H), 1.44 (dd, $J = 11.9, 7.7$ Hz, 1H), 0.91 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 185.6, 163.3, 150.4, 149.6, 136.4, 135.1, 130.1, 129.9, 127.9, 127.2, 126.1, 126.0, 125.0, 76.5, 51.6, 50.3, 46.6, 43.2, 36.1, 29.8, 29.1, 25.2, 23.6; IR (neat, cm^{-1}): 3367 (m), 3007 (w), 2924 (m), 2852 (m), 1662 (s); HRMS (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{27}\text{O}_2$ 359.2011; found 359.2002; $[\alpha]_{589}^{20.9}$: -17.5 (c 0.0001, CHCl_3).





Synthesis of Tetracycle 67: A solution of tetracycle **66**⁶ (16 mg, 0.0462 mmol, 1.0 equiv) in HFIP (2 mL) at 0 °C under N_2 atmosphere was stirred for 10 min before the addition of PIDA (14 mg, 0.0439 mmol, 0.95 equiv). The solution was stirred for no more than 1 min before being quenched with saturated aqueous NaHCO_3 (2 mL). HFIP was subsequently removed from the reaction mixture under vacuum, and the mostly aqueous remains was diluted with EtOAc (2 mL). The organic phase was separated, the aqueous phase was extracted with 3 x 20 mL EtOAc, and the combined organic phase was dried over MgSO_4 , filtered, and concentrated *in vacuo*. The resulting crude product was purified by flash chromatography using a gradient of 20–60% EtOAc in hexanes to afford **67** (11 mg, 0.032 mmol, 69%) as a white solid.


Data for Compound 67: For NMR Spectra of **67** see page S133. TLC: $R_f = 0.29$ (45% EtOAc in 45% hexanes with 10% CH_2Cl_2); ^1H NMR (600 MHz, CDCl_3): δ 7.33 – 7.30 (m, 2H), 7.27 – 7.24 (m, 1H), 7.21 (d, $J = 10.1$ Hz, 1H), 7.15 (d, $J = 7.3$ Hz, 2H), 6.47 (dd, $J = 10.3, 2.2$ Hz, 1H), 6.12 (s, 1H), 5.61 (s, 1H), 5.15 (app. t, $J = 7.0$ Hz, 1H), 2.82 – 2.76 (m, 1H), 2.46 – 2.37 (m, 2H), 2.37 – 2.27 (m, 3H), 2.24 – 2.17 (m, 1H), 1.86 – 1.81 (m, 1H), 1.73 (dt, $J = 12.8, 5.2$ Hz, 1H), 1.52 (dd, $J = 12.1, 7.7$ Hz, 1H), 0.98 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 186.3, 165.7, 150.8, 149.4, 139.8, 134.7, 129.1, 129.0, 128.9, 127.7, 127.7, 127.6, 125.3, 122.9, 76.5, 53.8, 51.5, 43.5, 36.0, 29.4, 29.3, 26.7, 23.7; IR (neat, cm^{-1}): 3392 (m), 3011 (m), 2924 (s), 2852 (m), 1732 (w), 1666 (s); HRMS (ESI-TOF) (m/z): $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{25}\text{O}_2$ 345.1855; found, 345.1847; $[\alpha]_{589}^{20.9}$: -60.8 (c 0.0004, CHCl_3).

3. NMR Spectra



^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of diol **S6**





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of phenol **S7**





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of aryl triflate **S8**





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of enyne **S10**





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **S14**





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **S16**





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **S17**




^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of hydrindane **S18**




^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of hydrindane **27**





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **21**




^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **22**





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **23**





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **S31**






^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **24**





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **25**





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **26**




^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **29**




^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **34**




^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **36**





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **38**





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **62**





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **40**





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of S32





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **42**





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of S33





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **41**





H NMR (600 MHz, CDCl₃) and ¹³C{¹H} NMR (150 MHz, CDCl₃) of **43**




^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **45**




^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **44**





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of S34




^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of S36





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **46**




^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of S21




^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **S37**




^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **47**





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of S22





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of S38





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **48**





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of S24




^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of S39





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **49**





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **S25**





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of S40





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **50**





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of S26




^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of S41





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **51**





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of S27





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of S42





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **52**




^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **S29**




¹H NMR (600 MHz, CDCl₃) and ¹³C{¹H} NMR (150 MHz, CDCl₃) of S43




^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **53**




^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of S46





^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **54**




^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **55**




^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **59**





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **60**




^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **61**




^1H NMR (600 MHz, CDCl_3) and $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) of **63**





^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **64**



^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **65**



^1H NMR (600 MHz, CDCl_3) and ^{13}C { ^1H } NMR (150 MHz, CDCl_3) of **67**



4. References:

1. Burchat, A. F.; Chong, J. M. Titration of Alkylolithiums with a Simple Reagent to a Blue Endpoint. *J. Organomet. Chem.* **1997**, *542*, 281–283.
2. Pflueger, J. J.; Morrill, L. C.; deGruyter, J. N.; Perea, M. A.; Sarpong, R. Magnesiate Addition/Ring-Expansion Strategy to Access the 6–7–6 Tricyclic Core of Hetisine-Type C20-Diterpenoid Alkaloids. *Org. Lett.* **2017**, *19*, 4632–4635.
3. Rahaim, R. J.; Shaw, J. T. Zinc-Catalyzed Silylation of Terminal Alkynes. *The Journal of Organic Chemistry* **2008**, *73*, 2912–2915.
4. Chiu, H. C.; Tonks, I. A. Trimethylsilyl-Protected Alkynes as Selective Cross-Coupling Partners in Titanium-Catalyzed [2+2+1] Pyrrole Synthesis. *Angewandte Chemie International Edition* **2018**, *57*, 6090–6094.
5. Xiang, K.; Tong, P.; Yan, B.; Long, L.; Zhao, C.; Zhang, Y.; Li, Y. *Org. Lett.* **2019**, *21*, 412–416.
6. Millham, A. B.; Bhatt, C. P.; Micalizio, G. C. From Metallacycle-Mediated Annulative Cross-Coupling to Steroidal Tetracycles through Intramolecular C9–C10 Bond Formation. *Org. Lett.* **2020**, *22*, 6595–6599.
7. Kim, W. S.; Shalit, Z. A.; Nguyen, S. M.; Schoepke, E.; Eastman, A.; Burris, T. P.; Gaur, A. B.; Micalizio, G. C. A Synthesis Strategy for Tetracyclic Terpenoids Leads to Agonists of ER β . *Nat. Commun.* **2019**, *10*, 2448.
8. From the corresponding vinyl bromide: Bigot, A.; Breuninger, D.; Breit, B. One-Pot Desymmetrizing Hydroformylation/Carbonyl Ene Cyclization Process: Straightforward Access to Highly Functionalized Cyclohexanols. *Org. Lett.* **2008**, *10* (23), 5321–5324.
9. Reddy, B. V. S., Borkar, P., Yadav, J. S., Sridhar, B. & Grée, R. Tandem Prins/Friedel–Crafts Cyclization for Stereoselective Synthesis of Heterotricyclic Systems. *The Journal of Organic Chemistry* **2011**, *76*, 7677–7690.
10. From the corresponding vinyl bromide: Groth, U.; Kesenheimer, C.; Kreye, P. Total Synthesis of (–)-Chokol A by an Asymmetric Domino Michael Addition–Dieckmann Cyclization. *Synlett.* **2006**, *14*, 2223–2226.
11. Hameury, T.; Guillemont, J.; Hijfte, L. V.; Bellosta, V.; Cossy, J. Diastereodivergent Addition of Allenylzincs to Aryl Glyoxylates. *Org. Lett.* **2009**, *11*, 2397–2400.
12. Mehta, G.; Yaragorla, S. A Concise, Enantiospecific, Hajos–Parrish Ketone Based Model Approach Toward the Tetracyclic Core or Complex Shiartane-Type Nortriterpenoid Natural Products. *Tetrahedron Lett.* **2013**, *54*, 549–552.